prompt
stringlengths 1.92k
9.98k
| response
stringlengths 714
11k
|
|---|---|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-566
Date of Submission: 2025-02-18
This report was submitted by a Other Healthcare Professional from Parker Group Medical Center concerning patient ANON-PX-5679. The subject is a 73-year-old female with a significant medical history including osteoarthritis, type 2 diabetes, coronary artery disease, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Warfarin (Anticoagulant) administered via the Intravenous route at a dosage of 117mg, initiated on 2024-12-15 for Thromboembolism prevention with the course ongoing.
On approximately 2025-02-01, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Headache, Hepatotoxicity, Anaphylaxis, Maculopapular Rash. The Stevens-Johnson syndrome was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Headache was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Hepatotoxicity was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed low and advised society. The current patient status regarding this symptom is 'Fatal'. The Anaphylaxis was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Maculopapular Rash was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 10 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Floor grow there military nearly. Amount natural report than nor read.</data>
|
report_id: ADR-2025-566
report_date: '2025-02-18'
patient_details:
patient_id: ANON-PX-5679
gender: Female
relevant_history:
- osteoarthritis
- type 2 diabetes
- coronary artery disease
- seasonal allergies
age_at_reaction: 73
suspected_drugs:
- drug_name: Warfarin
dosage: 117mg
route_of_administration: Intravenous
start_date: '2024-12-15'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-02-01'
severity: Severe
outcome: Recovered
intervention_required: false
- symptom_name: Headache
onset_date: '2025-02-01'
severity: Moderate
outcome: Not Recovered
intervention_required: false
- symptom_name: Hepatotoxicity
onset_date: '2025-02-01'
severity: Mild
outcome: Fatal
intervention_required: true
intervention_details: Prescribed low and advised society.
- symptom_name: Anaphylaxis
onset_date: '2025-02-01'
severity: Life-threatening
outcome: Fatal
intervention_required: false
- symptom_name: Maculopapular Rash
onset_date: '2025-02-01'
severity: Mild
outcome: Unknown
intervention_required: false
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 10
reporting_facility: Parker Group Medical Center
reporter_type: Other Healthcare Professional
notes: Floor grow there military nearly. Amount natural report than nor read.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-570
Date of Submission: 2025-06-12
This report was submitted by a Other Healthcare Professional from Sellers PLC Medical Center concerning patient ANON-PX-4615. The subject is a 58-year-old male with a significant medical history including chronic kidney disease, anxiety, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Warfarin (Anticoagulant) administered via the Intravenous route at a dosage of 80mg, initiated on 2025-05-25 for Thromboembolism prevention and discontinued on 2025-06-04.
On approximately 2025-05-26, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Anaphylaxis, Pruritus, Dizziness. The Maculopapular Rash was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed student and advised former. The current patient status regarding this symptom is 'Unknown'. The Anaphylaxis was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Pruritus was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Dizziness was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-570
report_date: '2025-06-12'
patient_details:
patient_id: ANON-PX-4615
gender: Male
relevant_history:
- chronic kidney disease
- anxiety
- migraines
age_at_reaction: 58
suspected_drugs:
- drug_name: Warfarin
dosage: 80mg
route_of_administration: Intravenous
start_date: '2025-05-25'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
end_date: '2025-06-04'
adverse_reactions:
- symptom_name: Maculopapular Rash
onset_date: '2025-05-26'
severity: Severe
outcome: Unknown
intervention_required: true
intervention_details: Prescribed student and advised former.
- symptom_name: Anaphylaxis
onset_date: '2025-05-26'
severity: Moderate
outcome: Not Recovered
intervention_required: false
- symptom_name: Pruritus
onset_date: '2025-05-26'
severity: Life-threatening
outcome: Not Recovered
intervention_required: false
- symptom_name: Dizziness
onset_date: '2025-05-26'
severity: Life-threatening
outcome: Recovered
intervention_required: true
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 6
reporting_facility: Sellers PLC Medical Center
reporter_type: Other Healthcare Professional
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-547
Date of Submission: 2025-06-29
This report was submitted by a Patient from Mitchell-Gonzalez Medical Center concerning patient ANON-PX-9567. The subject is a 56-year-old other with a significant medical history including coronary artery disease, atrial fibrillation, osteoarthritis, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Amoxicillin (Penicillin antibiotic) administered via the Intravenous route at a dosage of 369mg, initiated on 2025-05-26 for Bacterial infection and discontinued on 2025-06-25; Ibuprofen (NSAID) administered via the Intravenous route at a dosage of 148mg, initiated on 2025-05-26 for Pain and inflammation and discontinued on 2025-06-25.
On approximately 2025-06-19, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Angioedema, Nausea, Hepatotoxicity. The Anaphylaxis was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed rest and advised machine. The current patient status regarding this symptom is 'Unknown'. The Angioedema was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Nausea was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Hepatotoxicity was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed try and advised subject. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-547
report_date: '2025-06-29'
patient_details:
patient_id: ANON-PX-9567
gender: Other
relevant_history:
- coronary artery disease
- atrial fibrillation
- osteoarthritis
- asthma
age_at_reaction: 56
suspected_drugs:
- drug_name: Amoxicillin
dosage: 369mg
route_of_administration: Intravenous
start_date: '2025-05-26'
indication_for_use: Bacterial infection
drug_class: Penicillin antibiotic
end_date: '2025-06-25'
- drug_name: Ibuprofen
dosage: 148mg
route_of_administration: Intravenous
start_date: '2025-05-26'
indication_for_use: Pain and inflammation
drug_class: NSAID
end_date: '2025-06-25'
adverse_reactions:
- symptom_name: Anaphylaxis
onset_date: '2025-06-19'
severity: Severe
outcome: Unknown
intervention_required: true
intervention_details: Prescribed rest and advised machine.
- symptom_name: Angioedema
onset_date: '2025-06-19'
severity: Severe
outcome: Recovering
intervention_required: false
- symptom_name: Nausea
onset_date: '2025-06-19'
severity: Severe
outcome: Recovering
intervention_required: false
- symptom_name: Hepatotoxicity
onset_date: '2025-06-19'
severity: Life-threatening
outcome: Fatal
intervention_required: true
intervention_details: Prescribed try and advised subject.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 6
reporting_facility: Mitchell-Gonzalez Medical Center
reporter_type: Patient
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-344
Date of Submission: 2025-02-25
This report was submitted by a Patient from Wolfe-Moore Medical Center concerning patient ANON-PX-1929. The subject is a 75-year-old male with a significant medical history including anxiety, asthma, hypertension, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Topical route at a dosage of 171mg, initiated on 2024-12-16 for Pain and inflammation and discontinued on 2025-01-11; Omeprazole (Proton-pump inhibitor) administered via the Topical route at a dosage of 15mg, initiated on 2024-12-16 for Gastroesophageal reflux disease and discontinued on 2025-01-11.
On approximately 2024-12-23, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Pruritus, Maculopapular Rash, Stevens-Johnson syndrome, Anaphylaxis, Dizziness. The Pruritus was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Maculopapular Rash was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Stevens-Johnson syndrome was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed service and advised tonight. The current patient status regarding this symptom is 'Fatal'. The Anaphylaxis was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Dizziness was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed understand and advised moment. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 2 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-344
report_date: '2025-02-25'
patient_details:
patient_id: ANON-PX-1929
gender: Male
relevant_history:
- anxiety
- asthma
- hypertension
- atrial fibrillation
age_at_reaction: 75
suspected_drugs:
- drug_name: Ibuprofen
dosage: 171mg
route_of_administration: Topical
start_date: '2024-12-16'
indication_for_use: Pain and inflammation
drug_class: NSAID
end_date: '2025-01-11'
- drug_name: Omeprazole
dosage: 15mg
route_of_administration: Topical
start_date: '2024-12-16'
indication_for_use: Gastroesophageal reflux disease
drug_class: Proton-pump inhibitor
end_date: '2025-01-11'
adverse_reactions:
- symptom_name: Pruritus
onset_date: '2024-12-23'
severity: Mild
outcome: Recovering
intervention_required: false
- symptom_name: Maculopapular Rash
onset_date: '2024-12-23'
severity: Moderate
outcome: Fatal
intervention_required: false
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-12-23'
severity: Moderate
outcome: Fatal
intervention_required: true
intervention_details: Prescribed service and advised tonight.
- symptom_name: Anaphylaxis
onset_date: '2024-12-23'
severity: Moderate
outcome: Fatal
intervention_required: false
- symptom_name: Dizziness
onset_date: '2024-12-23'
severity: Life-threatening
outcome: Recovered
intervention_required: true
intervention_details: Prescribed understand and advised moment.
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 2
reporting_facility: Wolfe-Moore Medical Center
reporter_type: Patient
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-920
Date of Submission: 2025-04-02
This report was submitted by a Other Healthcare Professional from Johnson PLC Medical Center concerning patient ANON-PX-8576. The subject is a 71-year-old other with a significant medical history including osteoarthritis, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Levothyroxine administered via the Oral route at a dosage of 297mg, initiated on 2025-02-17 for Hypothyroidism and discontinued on 2025-03-28.
On approximately 2025-03-23, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Pruritus, Angioedema, Somnolence. The Hepatotoxicity was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Pruritus was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed husband and advised question. The current patient status regarding this symptom is 'Recovered'. The Angioedema was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. The Somnolence was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Allow me he unit. Compare fund lead decision. Throughout painting at region example.</data>
|
report_id: ADR-2025-920
report_date: '2025-04-02'
patient_details:
patient_id: ANON-PX-8576
gender: Other
relevant_history:
- osteoarthritis
- asthma
age_at_reaction: 71
suspected_drugs:
- drug_name: Levothyroxine
dosage: 297mg
route_of_administration: Oral
start_date: '2025-02-17'
indication_for_use: Hypothyroidism
end_date: '2025-03-28'
adverse_reactions:
- symptom_name: Hepatotoxicity
onset_date: '2025-03-23'
severity: Life-threatening
outcome: Fatal
intervention_required: false
- symptom_name: Pruritus
onset_date: '2025-03-23'
severity: Moderate
outcome: Recovered
intervention_required: true
intervention_details: Prescribed husband and advised question.
- symptom_name: Angioedema
onset_date: '2025-03-23'
severity: Severe
outcome: Fatal
intervention_required: true
- symptom_name: Somnolence
onset_date: '2025-03-23'
severity: Moderate
outcome: Fatal
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 5
reporting_facility: Johnson PLC Medical Center
reporter_type: Other Healthcare Professional
notes: Allow me he unit. Compare fund lead decision. Throughout painting at region
example.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-237
Date of Submission: 2025-03-08
This report was submitted by a Physician from Perez-Ayala Medical Center concerning patient ANON-PX-8263. The subject is a 39-year-old male with a significant medical history including hypertension, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Warfarin (Anticoagulant) administered via the Oral route at a dosage of 230mg, initiated on 2024-12-23 for Thromboembolism prevention and discontinued on 2025-01-18; Lisinopril (ACE inhibitor) administered via the Intramuscular route at a dosage of 47mg, initiated on 2024-12-23 for Hypertension and discontinued on 2025-01-18.
On approximately 2025-01-17, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Pruritus, Maculopapular Rash, Headache, Anaphylaxis, Stevens-Johnson syndrome. The Pruritus was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed audience and advised despite. The current patient status regarding this symptom is 'Recovering'. The Maculopapular Rash was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'. The Headache was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Anaphylaxis was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Stevens-Johnson syndrome was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 10 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Time help similar could. Process another interest start able building. Note experience loss part garden group.</data>
|
report_id: ADR-2025-237
report_date: '2025-03-08'
patient_details:
patient_id: ANON-PX-8263
gender: Male
relevant_history:
- hypertension
- coronary artery disease
age_at_reaction: 39
suspected_drugs:
- drug_name: Warfarin
dosage: 230mg
route_of_administration: Oral
start_date: '2024-12-23'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
end_date: '2025-01-18'
- drug_name: Lisinopril
dosage: 47mg
route_of_administration: Intramuscular
start_date: '2024-12-23'
indication_for_use: Hypertension
drug_class: ACE inhibitor
end_date: '2025-01-18'
adverse_reactions:
- symptom_name: Pruritus
onset_date: '2025-01-17'
severity: Mild
outcome: Recovering
intervention_required: true
intervention_details: Prescribed audience and advised despite.
- symptom_name: Maculopapular Rash
onset_date: '2025-01-17'
severity: Moderate
outcome: Not Recovered
intervention_required: true
- symptom_name: Headache
onset_date: '2025-01-17'
severity: Mild
outcome: Fatal
intervention_required: false
- symptom_name: Anaphylaxis
onset_date: '2025-01-17'
severity: Severe
outcome: Recovered
intervention_required: false
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-01-17'
severity: Moderate
outcome: Fatal
intervention_required: false
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 10
reporting_facility: Perez-Ayala Medical Center
reporter_type: Physician
notes: Time help similar could. Process another interest start able building. Note
experience loss part garden group.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-406
Date of Submission: 2025-06-16
This report was submitted by a Pharmacist from Taylor-Clark Medical Center concerning patient ANON-PX-8449. The subject is a 20-year-old male with a significant medical history including migraines, asthma, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Intramuscular route at a dosage of 31mg, initiated on 2025-05-03 for Pain and inflammation and discontinued on 2025-05-28; Omeprazole administered via the Subcutaneous route at a dosage of 494mg, initiated on 2025-05-03 for Gastroesophageal reflux disease and discontinued on 2025-05-28.
On approximately 2025-05-14, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Anaphylaxis, Dizziness, Somnolence, Vomiting. The Stevens-Johnson syndrome was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed herself and advised bring. The current patient status regarding this symptom is 'Recovering'. The Anaphylaxis was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Dizziness was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed page and advised bring. The current patient status regarding this symptom is 'Recovering'. The Somnolence was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Vomiting was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-406
report_date: '2025-06-16'
patient_details:
patient_id: ANON-PX-8449
gender: Male
relevant_history:
- migraines
- asthma
- chronic kidney disease
age_at_reaction: 20
suspected_drugs:
- drug_name: Ibuprofen
dosage: 31mg
route_of_administration: Intramuscular
start_date: '2025-05-03'
indication_for_use: Pain and inflammation
drug_class: NSAID
end_date: '2025-05-28'
- drug_name: Omeprazole
dosage: 494mg
route_of_administration: Subcutaneous
start_date: '2025-05-03'
indication_for_use: Gastroesophageal reflux disease
end_date: '2025-05-28'
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-05-14'
severity: Severe
outcome: Recovering
intervention_required: true
intervention_details: Prescribed herself and advised bring.
- symptom_name: Anaphylaxis
onset_date: '2025-05-14'
severity: Mild
outcome: Fatal
intervention_required: false
- symptom_name: Dizziness
onset_date: '2025-05-14'
severity: Severe
outcome: Recovering
intervention_required: true
intervention_details: Prescribed page and advised bring.
- symptom_name: Somnolence
onset_date: '2025-05-14'
severity: Severe
outcome: Unknown
intervention_required: false
- symptom_name: Vomiting
onset_date: '2025-05-14'
severity: Life-threatening
outcome: Recovering
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Rechallenge not performed
reporting_facility: Taylor-Clark Medical Center
reporter_type: Pharmacist
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-409
Date of Submission: 2024-11-04
This report was submitted by a Patient from Walker Ltd Medical Center concerning patient ANON-PX-4477. The subject is a 84-year-old female with a significant medical history including anxiety, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Lisinopril (ACE inhibitor) administered via the Topical route at a dosage of 81mg, initiated on 2024-08-14 for Hypertension and discontinued on 2024-09-28; Sertraline administered via the Oral route at a dosage of 127mg, initiated on 2024-08-14 for Major depressive disorder and discontinued on 2024-09-28.
On approximately 2024-09-11, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Headache. The Stevens-Johnson syndrome was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovering'. The Headache was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-409
report_date: '2024-11-04'
patient_details:
patient_id: ANON-PX-4477
gender: Female
relevant_history:
- anxiety
- type 2 diabetes
age_at_reaction: 84
suspected_drugs:
- drug_name: Lisinopril
dosage: 81mg
route_of_administration: Topical
start_date: '2024-08-14'
indication_for_use: Hypertension
drug_class: ACE inhibitor
end_date: '2024-09-28'
- drug_name: Sertraline
dosage: 127mg
route_of_administration: Oral
start_date: '2024-08-14'
indication_for_use: Major depressive disorder
end_date: '2024-09-28'
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-09-11'
severity: Moderate
outcome: Recovering
intervention_required: true
- symptom_name: Headache
onset_date: '2024-09-11'
severity: Moderate
outcome: Unknown
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Not applicable
reporting_facility: Walker Ltd Medical Center
reporter_type: Patient
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-521
Date of Submission: 2025-04-12
This report was submitted by a Patient from Hayes, Miller and Jackson Medical Center concerning patient ANON-PX-2819. The subject is an adult female with a significant medical history including chronic kidney disease, hypertension, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Omeprazole administered via the Topical route at a dosage of 69mg, initiated on 2025-03-09 for Gastroesophageal reflux disease with the course ongoing; Gabapentin (Anticonvulsant) administered via the Subcutaneous route at a dosage of 171mg, initiated on 2025-03-09 for Neuropathic pain with the course ongoing.
On approximately 2025-03-15, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Somnolence, Pruritus, Maculopapular Rash, Anaphylaxis, Dizziness. The Somnolence was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovering'. The Pruritus was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Maculopapular Rash was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Anaphylaxis was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed position and advised heavy. The current patient status regarding this symptom is 'Recovered'. The Dizziness was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 2 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-521
report_date: '2025-04-12'
patient_details:
patient_id: ANON-PX-2819
gender: Female
relevant_history:
- chronic kidney disease
- hypertension
- osteoarthritis
suspected_drugs:
- drug_name: Omeprazole
dosage: 69mg
route_of_administration: Topical
start_date: '2025-03-09'
indication_for_use: Gastroesophageal reflux disease
- drug_name: Gabapentin
dosage: 171mg
route_of_administration: Subcutaneous
start_date: '2025-03-09'
indication_for_use: Neuropathic pain
drug_class: Anticonvulsant
adverse_reactions:
- symptom_name: Somnolence
onset_date: '2025-03-15'
severity: Life-threatening
outcome: Recovering
intervention_required: true
- symptom_name: Pruritus
onset_date: '2025-03-15'
severity: Moderate
outcome: Unknown
intervention_required: false
- symptom_name: Maculopapular Rash
onset_date: '2025-03-15'
severity: Severe
outcome: Recovering
intervention_required: false
- symptom_name: Anaphylaxis
onset_date: '2025-03-15'
severity: Severe
outcome: Recovered
intervention_required: true
intervention_details: Prescribed position and advised heavy.
- symptom_name: Dizziness
onset_date: '2025-03-15'
severity: Severe
outcome: Recovering
intervention_required: false
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 2
reporting_facility: Hayes, Miller and Jackson Medical Center
reporter_type: Patient
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-508
Date of Submission: 2025-01-10
This report was submitted by a Patient from Garrison Inc Medical Center concerning patient ANON-PX-8813. The subject is an adult female with a significant medical history including chronic kidney disease, hypertension, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Omeprazole (Proton-pump inhibitor) administered via the Topical route at a dosage of 224mg, initiated on 2024-12-14 for Gastroesophageal reflux disease and discontinued on 2025-01-09; Sertraline (SSRI) administered via the Intravenous route at a dosage of 428mg, initiated on 2024-12-14 for Major depressive disorder and discontinued on 2025-01-09.
On approximately 2025-01-05, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Dizziness, Somnolence, Stevens-Johnson syndrome. The Headache was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed human and advised view. The current patient status regarding this symptom is 'Not Recovered'. The Dizziness was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed box and advised pass. The current patient status regarding this symptom is 'Fatal'. The Somnolence was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed short and advised well. The current patient status regarding this symptom is 'Recovering'. The Stevens-Johnson syndrome was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed second and advised Republican. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 2 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Prove either none opportunity travel. Save strong wrong instead part tonight standard. Talk article blue despite suddenly likely table lead. Professor increase reality language play if treatment.</data>
|
report_id: ADR-2025-508
report_date: '2025-01-10'
patient_details:
patient_id: ANON-PX-8813
gender: Female
relevant_history:
- chronic kidney disease
- hypertension
- asthma
suspected_drugs:
- drug_name: Omeprazole
dosage: 224mg
route_of_administration: Topical
start_date: '2024-12-14'
indication_for_use: Gastroesophageal reflux disease
drug_class: Proton-pump inhibitor
end_date: '2025-01-09'
- drug_name: Sertraline
dosage: 428mg
route_of_administration: Intravenous
start_date: '2024-12-14'
indication_for_use: Major depressive disorder
drug_class: SSRI
end_date: '2025-01-09'
adverse_reactions:
- symptom_name: Headache
onset_date: '2025-01-05'
severity: Life-threatening
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed human and advised view.
- symptom_name: Dizziness
onset_date: '2025-01-05'
severity: Moderate
outcome: Fatal
intervention_required: true
intervention_details: Prescribed box and advised pass.
- symptom_name: Somnolence
onset_date: '2025-01-05'
severity: Moderate
outcome: Recovering
intervention_required: true
intervention_details: Prescribed short and advised well.
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-01-05'
severity: Moderate
outcome: Recovered
intervention_required: true
intervention_details: Prescribed second and advised Republican.
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 2
reporting_facility: Garrison Inc Medical Center
reporter_type: Patient
notes: Prove either none opportunity travel. Save strong wrong instead part tonight
standard. Talk article blue despite suddenly likely table lead. Professor increase
reality language play if treatment.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-839
Date of Submission: 2024-11-01
This report was submitted by a Pharmacist from Duncan-Sellers Medical Center concerning patient ANON-PX-5474. The subject is a 84-year-old female with a significant medical history including seasonal allergies, anxiety, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Warfarin administered via the Oral route at a dosage of 240mg, initiated on 2024-10-23 for Thromboembolism prevention and discontinued on 2024-10-27.
On approximately 2024-10-26, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Pruritus, Somnolence. The Pruritus was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Somnolence was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Avoid realize memory water. Prove example learn join whether religious moment.</data>
|
report_id: ADR-2024-839
report_date: '2024-11-01'
patient_details:
patient_id: ANON-PX-5474
gender: Female
relevant_history:
- seasonal allergies
- anxiety
- atrial fibrillation
age_at_reaction: 84
suspected_drugs:
- drug_name: Warfarin
dosage: 240mg
route_of_administration: Oral
start_date: '2024-10-23'
indication_for_use: Thromboembolism prevention
end_date: '2024-10-27'
adverse_reactions:
- symptom_name: Pruritus
onset_date: '2024-10-26'
severity: Severe
outcome: Fatal
intervention_required: false
- symptom_name: Somnolence
onset_date: '2024-10-26'
severity: Mild
outcome: Not Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 6
reporting_facility: Duncan-Sellers Medical Center
reporter_type: Pharmacist
notes: Avoid realize memory water. Prove example learn join whether religious moment.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-385
Date of Submission: 2025-01-02
This report was submitted by a Other Healthcare Professional from Proctor Ltd Medical Center concerning patient ANON-PX-3266. The subject is a 60-year-old female with a significant medical history including atrial fibrillation, hypertension, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Metformin (Biguanide) administered via the Topical route at a dosage of 338mg, initiated on 2024-10-08 for Type 2 diabetes and discontinued on 2024-12-20; Omeprazole administered via the Intramuscular route at a dosage of 100mg, initiated on 2024-10-08 for Gastroesophageal reflux disease and discontinued on 2024-12-20.
On approximately 2024-11-01, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Vomiting, Dizziness, Headache, Diarrhea. The Stevens-Johnson syndrome was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Vomiting was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Dizziness was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed low and advised green. The current patient status regarding this symptom is 'Recovered'. The Headache was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed culture and advised action. The current patient status regarding this symptom is 'Recovering'. The Diarrhea was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 7 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Ask road he drop guess activity. Cultural visit court social media into resource. Specific send eight.</data>
|
report_id: ADR-2025-385
report_date: '2025-01-02'
patient_details:
patient_id: ANON-PX-3266
gender: Female
relevant_history:
- atrial fibrillation
- hypertension
- coronary artery disease
age_at_reaction: 60
suspected_drugs:
- drug_name: Metformin
dosage: 338mg
route_of_administration: Topical
start_date: '2024-10-08'
indication_for_use: Type 2 diabetes
drug_class: Biguanide
end_date: '2024-12-20'
- drug_name: Omeprazole
dosage: 100mg
route_of_administration: Intramuscular
start_date: '2024-10-08'
indication_for_use: Gastroesophageal reflux disease
end_date: '2024-12-20'
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-11-01'
severity: Life-threatening
outcome: Not Recovered
intervention_required: false
- symptom_name: Vomiting
onset_date: '2024-11-01'
severity: Moderate
outcome: Recovering
intervention_required: false
- symptom_name: Dizziness
onset_date: '2024-11-01'
severity: Severe
outcome: Recovered
intervention_required: true
intervention_details: Prescribed low and advised green.
- symptom_name: Headache
onset_date: '2024-11-01'
severity: Severe
outcome: Recovering
intervention_required: true
intervention_details: Prescribed culture and advised action.
- symptom_name: Diarrhea
onset_date: '2024-11-01'
severity: Severe
outcome: Not Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 7
reporting_facility: Proctor Ltd Medical Center
reporter_type: Other Healthcare Professional
notes: Ask road he drop guess activity. Cultural visit court social media into resource.
Specific send eight.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-705
Date of Submission: 2025-05-26
This report was submitted by a Nurse from Hampton, Bell and Wagner Medical Center concerning patient ANON-PX-4796. The subject is an adult female with a significant medical history including osteoarthritis, type 2 diabetes, seasonal allergies, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Oral route at a dosage of 357mg, initiated on 2025-04-28 for Neuropathic pain and discontinued on 2025-05-20; Sertraline (SSRI) administered via the Oral route at a dosage of 61mg, initiated on 2025-04-28 for Major depressive disorder and discontinued on 2025-05-20.
On approximately 2025-05-18, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Dizziness. The Hepatotoxicity was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Dizziness was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 2 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Feeling poor great little treat. Support speech by move son than race rock. Ten health article then professional democratic.</data>
|
report_id: ADR-2025-705
report_date: '2025-05-26'
patient_details:
patient_id: ANON-PX-4796
gender: Female
relevant_history:
- osteoarthritis
- type 2 diabetes
- seasonal allergies
- migraines
suspected_drugs:
- drug_name: Gabapentin
dosage: 357mg
route_of_administration: Oral
start_date: '2025-04-28'
indication_for_use: Neuropathic pain
drug_class: Anticonvulsant
end_date: '2025-05-20'
- drug_name: Sertraline
dosage: 61mg
route_of_administration: Oral
start_date: '2025-04-28'
indication_for_use: Major depressive disorder
drug_class: SSRI
end_date: '2025-05-20'
adverse_reactions:
- symptom_name: Hepatotoxicity
onset_date: '2025-05-18'
severity: Life-threatening
outcome: Fatal
intervention_required: false
- symptom_name: Dizziness
onset_date: '2025-05-18'
severity: Moderate
outcome: Recovering
intervention_required: false
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 2
reporting_facility: Hampton, Bell and Wagner Medical Center
reporter_type: Nurse
notes: Feeling poor great little treat. Support speech by move son than race rock.
Ten health article then professional democratic.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-892
Date of Submission: 2025-02-25
This report was submitted by a Patient from Edwards, Garza and Thompson Medical Center concerning patient ANON-PX-3104. The subject is a 44-year-old male with a significant medical history including migraines, seasonal allergies, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Metformin (Biguanide) administered via the Oral route at a dosage of 38mg, initiated on 2025-02-09 for Type 2 diabetes with the course ongoing; Omeprazole (Proton-pump inhibitor) administered via the Subcutaneous route at a dosage of 456mg, initiated on 2025-02-09 for Gastroesophageal reflux disease with the course ongoing.
On approximately 2025-02-19, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Pruritus, Maculopapular Rash, Somnolence, Anaphylaxis. The Pruritus was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Maculopapular Rash was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed size and advised case. The current patient status regarding this symptom is 'Recovered'. The Somnolence was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed option and advised home. The current patient status regarding this symptom is 'Not Recovered'. The Anaphylaxis was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed modern and advised turn. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Interest usually actually trial blood arm population. Read author describe back budget interesting. Significant admit name never cup top skin.</data>
|
report_id: ADR-2025-892
report_date: '2025-02-25'
patient_details:
patient_id: ANON-PX-3104
gender: Male
relevant_history:
- migraines
- seasonal allergies
- type 2 diabetes
age_at_reaction: 44
suspected_drugs:
- drug_name: Metformin
dosage: 38mg
route_of_administration: Oral
start_date: '2025-02-09'
indication_for_use: Type 2 diabetes
drug_class: Biguanide
- drug_name: Omeprazole
dosage: 456mg
route_of_administration: Subcutaneous
start_date: '2025-02-09'
indication_for_use: Gastroesophageal reflux disease
drug_class: Proton-pump inhibitor
adverse_reactions:
- symptom_name: Pruritus
onset_date: '2025-02-19'
severity: Moderate
outcome: Fatal
intervention_required: false
- symptom_name: Maculopapular Rash
onset_date: '2025-02-19'
severity: Life-threatening
outcome: Recovered
intervention_required: true
intervention_details: Prescribed size and advised case.
- symptom_name: Somnolence
onset_date: '2025-02-19'
severity: Moderate
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed option and advised home.
- symptom_name: Anaphylaxis
onset_date: '2025-02-19'
severity: Mild
outcome: Fatal
intervention_required: true
intervention_details: Prescribed modern and advised turn.
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 1
reporting_facility: Edwards, Garza and Thompson Medical Center
reporter_type: Patient
notes: Interest usually actually trial blood arm population. Read author describe
back budget interesting. Significant admit name never cup top skin.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-275
Date of Submission: 2024-10-26
This report was submitted by a Physician from Jones-Lee Medical Center concerning patient ANON-PX-8263. The subject is a 32-year-old male with a significant medical history including chronic kidney disease, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Amoxicillin (Penicillin antibiotic) administered via the Intravenous route at a dosage of 288mg, initiated on 2024-08-12 for Bacterial infection and discontinued on 2024-10-05.
On approximately 2024-10-04, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Anaphylaxis, Dizziness. The Headache was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed actually and advised sometimes. The current patient status regarding this symptom is 'Recovered'. The Anaphylaxis was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Dizziness was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 9 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Of probably financial another purpose likely range politics. Have benefit religious. Family contain free under occur.</data>
|
report_id: ADR-2024-275
report_date: '2024-10-26'
patient_details:
patient_id: ANON-PX-8263
gender: Male
relevant_history:
- chronic kidney disease
- anxiety
age_at_reaction: 32
suspected_drugs:
- drug_name: Amoxicillin
dosage: 288mg
route_of_administration: Intravenous
start_date: '2024-08-12'
indication_for_use: Bacterial infection
drug_class: Penicillin antibiotic
end_date: '2024-10-05'
adverse_reactions:
- symptom_name: Headache
onset_date: '2024-10-04'
severity: Moderate
outcome: Recovered
intervention_required: true
intervention_details: Prescribed actually and advised sometimes.
- symptom_name: Anaphylaxis
onset_date: '2024-10-04'
severity: Mild
outcome: Not Recovered
intervention_required: false
- symptom_name: Dizziness
onset_date: '2024-10-04'
severity: Mild
outcome: Not Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Not applicable
naranjo_score: 9
reporting_facility: Jones-Lee Medical Center
reporter_type: Physician
notes: Of probably financial another purpose likely range politics. Have benefit religious.
Family contain free under occur.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-443
Date of Submission: 2025-07-06
This report was submitted by a Other Healthcare Professional from Medina-Vega Medical Center concerning patient ANON-PX-2551. The subject is a 42-year-old female with a significant medical history including type 2 diabetes, coronary artery disease, anxiety, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Ibuprofen administered via the Topical route at a dosage of 192mg, initiated on 2025-06-09 for Pain and inflammation and discontinued on 2025-07-01.
On approximately 2025-06-25, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Angioedema, Maculopapular Rash. The Angioedema was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Maculopapular Rash was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 9 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-443
report_date: '2025-07-06'
patient_details:
patient_id: ANON-PX-2551
gender: Female
relevant_history:
- type 2 diabetes
- coronary artery disease
- anxiety
- osteoarthritis
age_at_reaction: 42
suspected_drugs:
- drug_name: Ibuprofen
dosage: 192mg
route_of_administration: Topical
start_date: '2025-06-09'
indication_for_use: Pain and inflammation
end_date: '2025-07-01'
adverse_reactions:
- symptom_name: Angioedema
onset_date: '2025-06-25'
severity: Life-threatening
outcome: Fatal
intervention_required: false
- symptom_name: Maculopapular Rash
onset_date: '2025-06-25'
severity: Severe
outcome: Not Recovered
intervention_required: true
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 9
reporting_facility: Medina-Vega Medical Center
reporter_type: Other Healthcare Professional
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-374
Date of Submission: 2024-12-05
This report was submitted by a Pharmacist from Wilkinson Inc Medical Center concerning patient ANON-PX-7885. The subject is a 18-year-old female with a significant medical history including coronary artery disease, seasonal allergies, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Lisinopril (ACE inhibitor) administered via the Subcutaneous route at a dosage of 34mg, initiated on 2024-09-17 for Hypertension and discontinued on 2024-10-29.
On approximately 2024-10-13, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Pruritus, Dizziness, Somnolence. The Hepatotoxicity was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. The Pruritus was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Dizziness was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed western and advised series. The current patient status regarding this symptom is 'Fatal'. The Somnolence was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed involve and advised company. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 2 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Score three hard indicate TV service. Participant tell popular commercial both almost. See in reach part help firm.</data>
|
report_id: ADR-2024-374
report_date: '2024-12-05'
patient_details:
patient_id: ANON-PX-7885
gender: Female
relevant_history:
- coronary artery disease
- seasonal allergies
- type 2 diabetes
age_at_reaction: 18
suspected_drugs:
- drug_name: Lisinopril
dosage: 34mg
route_of_administration: Subcutaneous
start_date: '2024-09-17'
indication_for_use: Hypertension
drug_class: ACE inhibitor
end_date: '2024-10-29'
adverse_reactions:
- symptom_name: Hepatotoxicity
onset_date: '2024-10-13'
severity: Moderate
outcome: Fatal
intervention_required: true
- symptom_name: Pruritus
onset_date: '2024-10-13'
severity: Moderate
outcome: Unknown
intervention_required: false
- symptom_name: Dizziness
onset_date: '2024-10-13'
severity: Moderate
outcome: Fatal
intervention_required: true
intervention_details: Prescribed western and advised series.
- symptom_name: Somnolence
onset_date: '2024-10-13'
severity: Moderate
outcome: Recovered
intervention_required: true
intervention_details: Prescribed involve and advised company.
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 2
reporting_facility: Wilkinson Inc Medical Center
reporter_type: Pharmacist
notes: Score three hard indicate TV service. Participant tell popular commercial both
almost. See in reach part help firm.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-777
Date of Submission: 2025-07-19
This report was submitted by a Other Healthcare Professional from Ramirez PLC Medical Center concerning patient ANON-PX-9376. The subject is a 20-year-old female with a significant medical history including type 2 diabetes, anxiety, chronic kidney disease, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Subcutaneous route at a dosage of 401mg, initiated on 2025-05-23 for Hypothyroidism and discontinued on 2025-06-27; Sertraline (SSRI) administered via the Subcutaneous route at a dosage of 221mg, initiated on 2025-05-23 for Major depressive disorder and discontinued on 2025-06-27.
On approximately 2025-06-22, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Headache, Dizziness, Pruritus, Stevens-Johnson syndrome. The Anaphylaxis was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed against and advised edge. The current patient status regarding this symptom is 'Not Recovered'. The Headache was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Dizziness was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. The Pruritus was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed need and advised attention. The current patient status regarding this symptom is 'Recovering'. The Stevens-Johnson syndrome was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Get popular ground unit hair service.</data>
|
report_id: ADR-2025-777
report_date: '2025-07-19'
patient_details:
patient_id: ANON-PX-9376
gender: Female
relevant_history:
- type 2 diabetes
- anxiety
- chronic kidney disease
- seasonal allergies
age_at_reaction: 20
suspected_drugs:
- drug_name: Levothyroxine
dosage: 401mg
route_of_administration: Subcutaneous
start_date: '2025-05-23'
indication_for_use: Hypothyroidism
drug_class: Thyroid hormone
end_date: '2025-06-27'
- drug_name: Sertraline
dosage: 221mg
route_of_administration: Subcutaneous
start_date: '2025-05-23'
indication_for_use: Major depressive disorder
drug_class: SSRI
end_date: '2025-06-27'
adverse_reactions:
- symptom_name: Anaphylaxis
onset_date: '2025-06-22'
severity: Severe
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed against and advised edge.
- symptom_name: Headache
onset_date: '2025-06-22'
severity: Moderate
outcome: Unknown
intervention_required: true
- symptom_name: Dizziness
onset_date: '2025-06-22'
severity: Mild
outcome: Fatal
intervention_required: true
- symptom_name: Pruritus
onset_date: '2025-06-22'
severity: Life-threatening
outcome: Recovering
intervention_required: true
intervention_details: Prescribed need and advised attention.
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-06-22'
severity: Life-threatening
outcome: Not Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Not applicable
naranjo_score: 1
reporting_facility: Ramirez PLC Medical Center
reporter_type: Other Healthcare Professional
notes: Get popular ground unit hair service.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-605
Date of Submission: 2024-09-01
This report was submitted by a Patient from Martinez, Curtis and Alvarez Medical Center concerning patient ANON-PX-9422. The subject is a 32-year-old other with a significant medical history including atrial fibrillation, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Sertraline (SSRI) administered via the Intramuscular route at a dosage of 490mg, initiated on 2024-08-18 for Major depressive disorder and discontinued on 2024-08-25.
On approximately 2024-08-24, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Diarrhea, Dizziness, Angioedema. The Headache was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed art and advised program. The current patient status regarding this symptom is 'Fatal'. The Diarrhea was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed again and advised one. The current patient status regarding this symptom is 'Unknown'. The Dizziness was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed Democrat and advised bad. The current patient status regarding this symptom is 'Fatal'. The Angioedema was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 2 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Leader shake information serve win drop task. Consider travel safe front. Main drop baby poor attention green assume place.</data>
|
report_id: ADR-2024-605
report_date: '2024-09-01'
patient_details:
patient_id: ANON-PX-9422
gender: Other
relevant_history:
- atrial fibrillation
- anxiety
age_at_reaction: 32
suspected_drugs:
- drug_name: Sertraline
dosage: 490mg
route_of_administration: Intramuscular
start_date: '2024-08-18'
indication_for_use: Major depressive disorder
drug_class: SSRI
end_date: '2024-08-25'
adverse_reactions:
- symptom_name: Headache
onset_date: '2024-08-24'
severity: Life-threatening
outcome: Fatal
intervention_required: true
intervention_details: Prescribed art and advised program.
- symptom_name: Diarrhea
onset_date: '2024-08-24'
severity: Severe
outcome: Unknown
intervention_required: true
intervention_details: Prescribed again and advised one.
- symptom_name: Dizziness
onset_date: '2024-08-24'
severity: Mild
outcome: Fatal
intervention_required: true
intervention_details: Prescribed Democrat and advised bad.
- symptom_name: Angioedema
onset_date: '2024-08-24'
severity: Moderate
outcome: Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 2
reporting_facility: Martinez, Curtis and Alvarez Medical Center
reporter_type: Patient
notes: Leader shake information serve win drop task. Consider travel safe front. Main
drop baby poor attention green assume place.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-771
Date of Submission: 2025-03-17
This report was submitted by a Other Healthcare Professional from Thompson-Villanueva Medical Center concerning patient ANON-PX-7237. The subject is a 42-year-old female with a significant medical history including asthma, migraines, osteoarthritis, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Oral route at a dosage of 144mg, initiated on 2025-03-08 for Hypothyroidism with the course ongoing; Warfarin (Anticoagulant) administered via the Subcutaneous route at a dosage of 174mg, initiated on 2025-03-08 for Thromboembolism prevention with the course ongoing.
On approximately 2025-03-09, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Somnolence, Pruritus, Dizziness. The Maculopapular Rash was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Somnolence was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed water and advised statement. The current patient status regarding this symptom is 'Recovered'. The Pruritus was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Dizziness was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 3 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Entire respond learn range.</data>
|
report_id: ADR-2025-771
report_date: '2025-03-17'
patient_details:
patient_id: ANON-PX-7237
gender: Female
relevant_history:
- asthma
- migraines
- osteoarthritis
- type 2 diabetes
age_at_reaction: 42
suspected_drugs:
- drug_name: Levothyroxine
dosage: 144mg
route_of_administration: Oral
start_date: '2025-03-08'
indication_for_use: Hypothyroidism
drug_class: Thyroid hormone
- drug_name: Warfarin
dosage: 174mg
route_of_administration: Subcutaneous
start_date: '2025-03-08'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
adverse_reactions:
- symptom_name: Maculopapular Rash
onset_date: '2025-03-09'
severity: Life-threatening
outcome: Recovering
intervention_required: false
- symptom_name: Somnolence
onset_date: '2025-03-09'
severity: Severe
outcome: Recovered
intervention_required: true
intervention_details: Prescribed water and advised statement.
- symptom_name: Pruritus
onset_date: '2025-03-09'
severity: Life-threatening
outcome: Recovering
intervention_required: false
- symptom_name: Dizziness
onset_date: '2025-03-09'
severity: Life-threatening
outcome: Not Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 3
reporting_facility: Thompson-Villanueva Medical Center
reporter_type: Other Healthcare Professional
notes: Entire respond learn range.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-469
Date of Submission: 2024-10-16
This report was submitted by a Physician from Munoz-Gray Medical Center concerning patient ANON-PX-1156. The subject is an adult other with a significant medical history including asthma, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Oral route at a dosage of 186mg, initiated on 2024-08-03 for Pain and inflammation and discontinued on 2024-08-12; Levothyroxine (Thyroid hormone) administered via the Intravenous route at a dosage of 139mg, initiated on 2024-08-03 for Hypothyroidism and discontinued on 2024-08-12.
On approximately 2024-08-10, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Pruritus, Nausea. The Maculopapular Rash was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovering'. The Pruritus was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed view and advised director. The current patient status regarding this symptom is 'Unknown'. The Nausea was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 2 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Just action great green three billion. Here agent responsibility discussion.</data>
|
report_id: ADR-2024-469
report_date: '2024-10-16'
patient_details:
patient_id: ANON-PX-1156
gender: Other
relevant_history:
- asthma
- coronary artery disease
suspected_drugs:
- drug_name: Ibuprofen
dosage: 186mg
route_of_administration: Oral
start_date: '2024-08-03'
indication_for_use: Pain and inflammation
drug_class: NSAID
end_date: '2024-08-12'
- drug_name: Levothyroxine
dosage: 139mg
route_of_administration: Intravenous
start_date: '2024-08-03'
indication_for_use: Hypothyroidism
drug_class: Thyroid hormone
end_date: '2024-08-12'
adverse_reactions:
- symptom_name: Maculopapular Rash
onset_date: '2024-08-10'
severity: Moderate
outcome: Recovering
intervention_required: true
- symptom_name: Pruritus
onset_date: '2024-08-10'
severity: Mild
outcome: Unknown
intervention_required: true
intervention_details: Prescribed view and advised director.
- symptom_name: Nausea
onset_date: '2024-08-10'
severity: Moderate
outcome: Recovering
intervention_required: false
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 2
reporting_facility: Munoz-Gray Medical Center
reporter_type: Physician
notes: Just action great green three billion. Here agent responsibility discussion.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-651
Date of Submission: 2024-09-23
This report was submitted by a Physician from Ramsey, Lee and Lopez Medical Center concerning patient ANON-PX-6352. The subject is a 58-year-old other with a significant medical history including asthma, anxiety, migraines, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Omeprazole (Proton-pump inhibitor) administered via the Intravenous route at a dosage of 171mg, initiated on 2024-08-26 for Gastroesophageal reflux disease and discontinued on 2024-09-12.
On approximately 2024-09-12, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Hepatotoxicity, Headache, Anaphylaxis. The Stevens-Johnson syndrome was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Hepatotoxicity was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed add and advised someone. The current patient status regarding this symptom is 'Not Recovered'. The Headache was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Anaphylaxis was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 9 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Strategy then after inside.</data>
|
report_id: ADR-2024-651
report_date: '2024-09-23'
patient_details:
patient_id: ANON-PX-6352
gender: Other
relevant_history:
- asthma
- anxiety
- migraines
- chronic kidney disease
age_at_reaction: 58
suspected_drugs:
- drug_name: Omeprazole
dosage: 171mg
route_of_administration: Intravenous
start_date: '2024-08-26'
indication_for_use: Gastroesophageal reflux disease
drug_class: Proton-pump inhibitor
end_date: '2024-09-12'
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-09-12'
severity: Mild
outcome: Fatal
intervention_required: false
- symptom_name: Hepatotoxicity
onset_date: '2024-09-12'
severity: Severe
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed add and advised someone.
- symptom_name: Headache
onset_date: '2024-09-12'
severity: Severe
outcome: Recovered
intervention_required: false
- symptom_name: Anaphylaxis
onset_date: '2024-09-12'
severity: Mild
outcome: Recovering
intervention_required: false
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 9
reporting_facility: Ramsey, Lee and Lopez Medical Center
reporter_type: Physician
notes: Strategy then after inside.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-383
Date of Submission: 2024-09-18
This report was submitted by a Other Healthcare Professional from James Ltd Medical Center concerning patient ANON-PX-5415. The subject is an adult female with a significant medical history including atrial fibrillation, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Metformin (Biguanide) administered via the Intramuscular route at a dosage of 55mg, initiated on 2024-07-25 for Type 2 diabetes and discontinued on 2024-09-16; Sertraline (SSRI) administered via the Oral route at a dosage of 334mg, initiated on 2024-07-25 for Major depressive disorder and discontinued on 2024-09-16.
On approximately 2024-09-15, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Maculopapular Rash. The Dizziness was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Maculopapular Rash was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed energy and advised positive. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Letter pick financial message life foot guy. War position letter brother they natural everybody material. Late ready read performance would paper.</data>
|
report_id: ADR-2024-383
report_date: '2024-09-18'
patient_details:
patient_id: ANON-PX-5415
gender: Female
relevant_history:
- atrial fibrillation
- type 2 diabetes
suspected_drugs:
- drug_name: Metformin
dosage: 55mg
route_of_administration: Intramuscular
start_date: '2024-07-25'
indication_for_use: Type 2 diabetes
drug_class: Biguanide
end_date: '2024-09-16'
- drug_name: Sertraline
dosage: 334mg
route_of_administration: Oral
start_date: '2024-07-25'
indication_for_use: Major depressive disorder
drug_class: SSRI
end_date: '2024-09-16'
adverse_reactions:
- symptom_name: Dizziness
onset_date: '2024-09-15'
severity: Severe
outcome: Unknown
intervention_required: false
- symptom_name: Maculopapular Rash
onset_date: '2024-09-15'
severity: Severe
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed energy and advised positive.
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 1
reporting_facility: James Ltd Medical Center
reporter_type: Other Healthcare Professional
notes: Letter pick financial message life foot guy. War position letter brother they
natural everybody material. Late ready read performance would paper.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-960
Date of Submission: 2025-06-20
This report was submitted by a Other Healthcare Professional from Brooks Group Medical Center concerning patient ANON-PX-3534. The subject is a 31-year-old female with a significant medical history including seasonal allergies, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Warfarin (Anticoagulant) administered via the Intravenous route at a dosage of 352mg, initiated on 2025-04-11 for Thromboembolism prevention and discontinued on 2025-06-09; Sertraline administered via the Intramuscular route at a dosage of 267mg, initiated on 2025-04-11 for Major depressive disorder and discontinued on 2025-06-09.
On approximately 2025-04-24, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Anaphylaxis. The Maculopapular Rash was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'. The Anaphylaxis was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Else song adult maybe hour.</data>
|
report_id: ADR-2025-960
report_date: '2025-06-20'
patient_details:
patient_id: ANON-PX-3534
gender: Female
relevant_history:
- seasonal allergies
- hypertension
age_at_reaction: 31
suspected_drugs:
- drug_name: Warfarin
dosage: 352mg
route_of_administration: Intravenous
start_date: '2025-04-11'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
end_date: '2025-06-09'
- drug_name: Sertraline
dosage: 267mg
route_of_administration: Intramuscular
start_date: '2025-04-11'
indication_for_use: Major depressive disorder
end_date: '2025-06-09'
adverse_reactions:
- symptom_name: Maculopapular Rash
onset_date: '2025-04-24'
severity: Moderate
outcome: Not Recovered
intervention_required: true
- symptom_name: Anaphylaxis
onset_date: '2025-04-24'
severity: Severe
outcome: Recovering
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Not applicable
naranjo_score: 5
reporting_facility: Brooks Group Medical Center
reporter_type: Other Healthcare Professional
notes: Else song adult maybe hour.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-811
Date of Submission: 2025-02-11
This report was submitted by a Pharmacist from Keller Group Medical Center concerning patient ANON-PX-2640. The subject is a 53-year-old other with a significant medical history including migraines, osteoarthritis, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Intravenous route at a dosage of 23mg, initiated on 2024-12-02 for Hypothyroidism and discontinued on 2025-02-09; Sertraline administered via the Intravenous route at a dosage of 363mg, initiated on 2024-12-02 for Major depressive disorder and discontinued on 2025-02-09.
On approximately 2025-02-07, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Nausea, Anaphylaxis, Maculopapular Rash. The Headache was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Nausea was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Anaphylaxis was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed however and advised success. The current patient status regarding this symptom is 'Fatal'. The Maculopapular Rash was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed could and advised some. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 9 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Treat those behavior society just. Perform finish check speech degree medical. Us throughout catch firm serious budget main task.</data>
|
report_id: ADR-2025-811
report_date: '2025-02-11'
patient_details:
patient_id: ANON-PX-2640
gender: Other
relevant_history:
- migraines
- osteoarthritis
- coronary artery disease
age_at_reaction: 53
suspected_drugs:
- drug_name: Levothyroxine
dosage: 23mg
route_of_administration: Intravenous
start_date: '2024-12-02'
indication_for_use: Hypothyroidism
drug_class: Thyroid hormone
end_date: '2025-02-09'
- drug_name: Sertraline
dosage: 363mg
route_of_administration: Intravenous
start_date: '2024-12-02'
indication_for_use: Major depressive disorder
end_date: '2025-02-09'
adverse_reactions:
- symptom_name: Headache
onset_date: '2025-02-07'
severity: Life-threatening
outcome: Recovered
intervention_required: true
- symptom_name: Nausea
onset_date: '2025-02-07'
severity: Life-threatening
outcome: Recovered
intervention_required: false
- symptom_name: Anaphylaxis
onset_date: '2025-02-07'
severity: Moderate
outcome: Fatal
intervention_required: true
intervention_details: Prescribed however and advised success.
- symptom_name: Maculopapular Rash
onset_date: '2025-02-07'
severity: Moderate
outcome: Fatal
intervention_required: true
intervention_details: Prescribed could and advised some.
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Not applicable
naranjo_score: 9
reporting_facility: Keller Group Medical Center
reporter_type: Pharmacist
notes: Treat those behavior society just. Perform finish check speech degree medical.
Us throughout catch firm serious budget main task.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-158
Date of Submission: 2025-07-09
This report was submitted by a Other Healthcare Professional from Ward, Flores and Hernandez Medical Center concerning patient ANON-PX-8681. The subject is a 22-year-old other with a significant medical history including chronic kidney disease, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Topical route at a dosage of 363mg, initiated on 2025-05-04 for Neuropathic pain with the course ongoing; Warfarin (Anticoagulant) administered via the Intravenous route at a dosage of 162mg, initiated on 2025-05-04 for Thromboembolism prevention with the course ongoing.
On approximately 2025-05-12, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Angioedema, Stevens-Johnson syndrome. The Angioedema was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Stevens-Johnson syndrome was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed father and advised happen. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 10 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Well ahead rather look face already lose. Someone discuss bar know future amount.</data>
|
report_id: ADR-2025-158
report_date: '2025-07-09'
patient_details:
patient_id: ANON-PX-8681
gender: Other
relevant_history:
- chronic kidney disease
- atrial fibrillation
age_at_reaction: 22
suspected_drugs:
- drug_name: Gabapentin
dosage: 363mg
route_of_administration: Topical
start_date: '2025-05-04'
indication_for_use: Neuropathic pain
drug_class: Anticonvulsant
- drug_name: Warfarin
dosage: 162mg
route_of_administration: Intravenous
start_date: '2025-05-04'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
adverse_reactions:
- symptom_name: Angioedema
onset_date: '2025-05-12'
severity: Severe
outcome: Not Recovered
intervention_required: false
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-05-12'
severity: Severe
outcome: Recovering
intervention_required: true
intervention_details: Prescribed father and advised happen.
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 10
reporting_facility: Ward, Flores and Hernandez Medical Center
reporter_type: Other Healthcare Professional
notes: Well ahead rather look face already lose. Someone discuss bar know future amount.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-606
Date of Submission: 2024-10-08
This report was submitted by a Other Healthcare Professional from Hays, Sutton and Haynes Medical Center concerning patient ANON-PX-7241. The subject is an adult male with a significant medical history including osteoarthritis, seasonal allergies, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Atorvastatin (Statin) administered via the Topical route at a dosage of 398mg, initiated on 2024-08-23 for Hypercholesterolemia and discontinued on 2024-09-10; Lisinopril (ACE inhibitor) administered via the Intravenous route at a dosage of 402mg, initiated on 2024-08-23 for Hypertension and discontinued on 2024-09-10.
On approximately 2024-09-08, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Diarrhea, Dizziness. The Stevens-Johnson syndrome was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed address and advised soon. The current patient status regarding this symptom is 'Fatal'. The Diarrhea was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed war and advised address. The current patient status regarding this symptom is 'Not Recovered'. The Dizziness was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Sister me reality manage within produce. Condition wide activity score account them executive. Nation especially husband life save task.</data>
|
report_id: ADR-2024-606
report_date: '2024-10-08'
patient_details:
patient_id: ANON-PX-7241
gender: Male
relevant_history:
- osteoarthritis
- seasonal allergies
- type 2 diabetes
suspected_drugs:
- drug_name: Atorvastatin
dosage: 398mg
route_of_administration: Topical
start_date: '2024-08-23'
indication_for_use: Hypercholesterolemia
drug_class: Statin
end_date: '2024-09-10'
- drug_name: Lisinopril
dosage: 402mg
route_of_administration: Intravenous
start_date: '2024-08-23'
indication_for_use: Hypertension
drug_class: ACE inhibitor
end_date: '2024-09-10'
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-09-08'
severity: Mild
outcome: Fatal
intervention_required: true
intervention_details: Prescribed address and advised soon.
- symptom_name: Diarrhea
onset_date: '2024-09-08'
severity: Mild
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed war and advised address.
- symptom_name: Dizziness
onset_date: '2024-09-08'
severity: Severe
outcome: Not Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 6
reporting_facility: Hays, Sutton and Haynes Medical Center
reporter_type: Other Healthcare Professional
notes: Sister me reality manage within produce. Condition wide activity score account
them executive. Nation especially husband life save task.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-697
Date of Submission: 2025-03-19
This report was submitted by a Other Healthcare Professional from Carroll, Garner and Miller Medical Center concerning patient ANON-PX-1923. The subject is a 22-year-old other with a significant medical history including osteoarthritis, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Sertraline (SSRI) administered via the Intravenous route at a dosage of 86mg, initiated on 2025-01-22 for Major depressive disorder with the course ongoing; Warfarin (Anticoagulant) administered via the Topical route at a dosage of 306mg, initiated on 2025-01-22 for Thromboembolism prevention with the course ongoing.
On approximately 2025-02-02, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Diarrhea, Nausea. The Stevens-Johnson syndrome was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed check and advised professional. The current patient status regarding this symptom is 'Recovering'. The Diarrhea was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Nausea was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-697
report_date: '2025-03-19'
patient_details:
patient_id: ANON-PX-1923
gender: Other
relevant_history:
- osteoarthritis
- asthma
age_at_reaction: 22
suspected_drugs:
- drug_name: Sertraline
dosage: 86mg
route_of_administration: Intravenous
start_date: '2025-01-22'
indication_for_use: Major depressive disorder
drug_class: SSRI
- drug_name: Warfarin
dosage: 306mg
route_of_administration: Topical
start_date: '2025-01-22'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-02-02'
severity: Mild
outcome: Recovering
intervention_required: true
intervention_details: Prescribed check and advised professional.
- symptom_name: Diarrhea
onset_date: '2025-02-02'
severity: Life-threatening
outcome: Unknown
intervention_required: false
- symptom_name: Nausea
onset_date: '2025-02-02'
severity: Life-threatening
outcome: Not Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 1
reporting_facility: Carroll, Garner and Miller Medical Center
reporter_type: Other Healthcare Professional
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-351
Date of Submission: 2024-11-27
This report was submitted by a Nurse from Mclaughlin-Hall Medical Center concerning patient ANON-PX-1114. The subject is an adult female with a significant medical history including coronary artery disease, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Warfarin administered via the Subcutaneous route at a dosage of 459mg, initiated on 2024-11-01 for Thromboembolism prevention and discontinued on 2024-11-09; Lisinopril (ACE inhibitor) administered via the Intravenous route at a dosage of 162mg, initiated on 2024-11-01 for Hypertension and discontinued on 2024-11-09.
On approximately 2024-11-06, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Nausea, Dizziness. The Hepatotoxicity was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed water and advised now. The current patient status regarding this symptom is 'Recovered'. The Nausea was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Dizziness was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed of and advised pass. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Rich year chance hot machine. Surface add example task successful force.</data>
|
report_id: ADR-2024-351
report_date: '2024-11-27'
patient_details:
patient_id: ANON-PX-1114
gender: Female
relevant_history:
- coronary artery disease
- atrial fibrillation
suspected_drugs:
- drug_name: Warfarin
dosage: 459mg
route_of_administration: Subcutaneous
start_date: '2024-11-01'
indication_for_use: Thromboembolism prevention
end_date: '2024-11-09'
- drug_name: Lisinopril
dosage: 162mg
route_of_administration: Intravenous
start_date: '2024-11-01'
indication_for_use: Hypertension
drug_class: ACE inhibitor
end_date: '2024-11-09'
adverse_reactions:
- symptom_name: Hepatotoxicity
onset_date: '2024-11-06'
severity: Mild
outcome: Recovered
intervention_required: true
intervention_details: Prescribed water and advised now.
- symptom_name: Nausea
onset_date: '2024-11-06'
severity: Severe
outcome: Recovered
intervention_required: false
- symptom_name: Dizziness
onset_date: '2024-11-06'
severity: Mild
outcome: Recovered
intervention_required: true
intervention_details: Prescribed of and advised pass.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Rechallenge not performed
reporting_facility: Mclaughlin-Hall Medical Center
reporter_type: Nurse
notes: Rich year chance hot machine. Surface add example task successful force.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-990
Date of Submission: 2024-09-01
This report was submitted by a Pharmacist from Boyd, Martin and Underwood Medical Center concerning patient ANON-PX-8410. The subject is an adult female with a significant medical history including migraines, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Omeprazole administered via the Intramuscular route at a dosage of 224mg, initiated on 2024-06-08 for Gastroesophageal reflux disease and discontinued on 2024-08-27.
On approximately 2024-08-24, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Diarrhea, Headache, Stevens-Johnson syndrome, Anaphylaxis, Dizziness. The Diarrhea was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed drive and advised beautiful. The current patient status regarding this symptom is 'Fatal'. The Headache was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Stevens-Johnson syndrome was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed meet and advised child. The current patient status regarding this symptom is 'Unknown'. The Anaphylaxis was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Dizziness was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: President quickly environmental evening look official. Event identify last sense. Indicate over difference policy relate.</data>
|
report_id: ADR-2024-990
report_date: '2024-09-01'
patient_details:
patient_id: ANON-PX-8410
gender: Female
relevant_history:
- migraines
- hypertension
suspected_drugs:
- drug_name: Omeprazole
dosage: 224mg
route_of_administration: Intramuscular
start_date: '2024-06-08'
indication_for_use: Gastroesophageal reflux disease
end_date: '2024-08-27'
adverse_reactions:
- symptom_name: Diarrhea
onset_date: '2024-08-24'
severity: Life-threatening
outcome: Fatal
intervention_required: true
intervention_details: Prescribed drive and advised beautiful.
- symptom_name: Headache
onset_date: '2024-08-24'
severity: Life-threatening
outcome: Recovered
intervention_required: true
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-08-24'
severity: Moderate
outcome: Unknown
intervention_required: true
intervention_details: Prescribed meet and advised child.
- symptom_name: Anaphylaxis
onset_date: '2024-08-24'
severity: Mild
outcome: Unknown
intervention_required: false
- symptom_name: Dizziness
onset_date: '2024-08-24'
severity: Severe
outcome: Recovering
intervention_required: true
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 5
reporting_facility: Boyd, Martin and Underwood Medical Center
reporter_type: Pharmacist
notes: President quickly environmental evening look official. Event identify last
sense. Indicate over difference policy relate.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-421
Date of Submission: 2024-11-30
This report was submitted by a Nurse from Singh-Sherman Medical Center concerning patient ANON-PX-6075. The subject is an adult male with a significant medical history including migraines, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Ibuprofen administered via the Oral route at a dosage of 140mg, initiated on 2024-10-22 for Pain and inflammation with the course ongoing; Gabapentin (Anticonvulsant) administered via the Intravenous route at a dosage of 317mg, initiated on 2024-10-22 for Neuropathic pain with the course ongoing.
On approximately 2024-11-07, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Nausea, Stevens-Johnson syndrome. The Nausea was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Stevens-Johnson syndrome was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Other go boy. Receive guy include ten water personal not.</data>
|
report_id: ADR-2024-421
report_date: '2024-11-30'
patient_details:
patient_id: ANON-PX-6075
gender: Male
relevant_history:
- migraines
- type 2 diabetes
suspected_drugs:
- drug_name: Ibuprofen
dosage: 140mg
route_of_administration: Oral
start_date: '2024-10-22'
indication_for_use: Pain and inflammation
- drug_name: Gabapentin
dosage: 317mg
route_of_administration: Intravenous
start_date: '2024-10-22'
indication_for_use: Neuropathic pain
drug_class: Anticonvulsant
adverse_reactions:
- symptom_name: Nausea
onset_date: '2024-11-07'
severity: Life-threatening
outcome: Not Recovered
intervention_required: false
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-11-07'
severity: Mild
outcome: Unknown
intervention_required: false
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 1
reporting_facility: Singh-Sherman Medical Center
reporter_type: Nurse
notes: Other go boy. Receive guy include ten water personal not.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-360
Date of Submission: 2024-09-25
This report was submitted by a Pharmacist from Gregory PLC Medical Center concerning patient ANON-PX-5162. The subject is an adult other with a significant medical history including coronary artery disease, seasonal allergies, migraines, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Warfarin (Anticoagulant) administered via the Subcutaneous route at a dosage of 389mg, initiated on 2024-08-07 for Thromboembolism prevention and discontinued on 2024-09-23; Metformin (Biguanide) administered via the Intravenous route at a dosage of 141mg, initiated on 2024-08-07 for Type 2 diabetes and discontinued on 2024-09-23.
On approximately 2024-09-23, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Nausea, Diarrhea, Stevens-Johnson syndrome, Somnolence. The Nausea was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Diarrhea was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed single and advised charge. The current patient status regarding this symptom is 'Recovering'. The Stevens-Johnson syndrome was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Somnolence was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed early and advised assume. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-360
report_date: '2024-09-25'
patient_details:
patient_id: ANON-PX-5162
gender: Other
relevant_history:
- coronary artery disease
- seasonal allergies
- migraines
- chronic kidney disease
suspected_drugs:
- drug_name: Warfarin
dosage: 389mg
route_of_administration: Subcutaneous
start_date: '2024-08-07'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
end_date: '2024-09-23'
- drug_name: Metformin
dosage: 141mg
route_of_administration: Intravenous
start_date: '2024-08-07'
indication_for_use: Type 2 diabetes
drug_class: Biguanide
end_date: '2024-09-23'
adverse_reactions:
- symptom_name: Nausea
onset_date: '2024-09-23'
severity: Mild
outcome: Unknown
intervention_required: false
- symptom_name: Diarrhea
onset_date: '2024-09-23'
severity: Mild
outcome: Recovering
intervention_required: true
intervention_details: Prescribed single and advised charge.
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-09-23'
severity: Moderate
outcome: Unknown
intervention_required: false
- symptom_name: Somnolence
onset_date: '2024-09-23'
severity: Moderate
outcome: Recovered
intervention_required: true
intervention_details: Prescribed early and advised assume.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 5
reporting_facility: Gregory PLC Medical Center
reporter_type: Pharmacist
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-478
Date of Submission: 2025-03-17
This report was submitted by a Pharmacist from Flores, Petersen and Lin Medical Center concerning patient ANON-PX-9089. The subject is a 30-year-old other with a significant medical history including seasonal allergies, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Omeprazole (Proton-pump inhibitor) administered via the Oral route at a dosage of 394mg, initiated on 2025-02-04 for Gastroesophageal reflux disease and discontinued on 2025-03-05.
On approximately 2025-02-08, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Nausea, Somnolence, Hepatotoxicity, Maculopapular Rash. The Nausea was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed cup and advised meeting. The current patient status regarding this symptom is 'Unknown'. The Somnolence was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed article and advised fish. The current patient status regarding this symptom is 'Fatal'. The Hepatotoxicity was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed health and advised two. The current patient status regarding this symptom is 'Not Recovered'. The Maculopapular Rash was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Risk school condition because five. Painting coach inside sign fall. Key drug discussion structure debate these.</data>
|
report_id: ADR-2025-478
report_date: '2025-03-17'
patient_details:
patient_id: ANON-PX-9089
gender: Other
relevant_history:
- seasonal allergies
- anxiety
age_at_reaction: 30
suspected_drugs:
- drug_name: Omeprazole
dosage: 394mg
route_of_administration: Oral
start_date: '2025-02-04'
indication_for_use: Gastroesophageal reflux disease
drug_class: Proton-pump inhibitor
end_date: '2025-03-05'
adverse_reactions:
- symptom_name: Nausea
onset_date: '2025-02-08'
severity: Moderate
outcome: Unknown
intervention_required: true
intervention_details: Prescribed cup and advised meeting.
- symptom_name: Somnolence
onset_date: '2025-02-08'
severity: Mild
outcome: Fatal
intervention_required: true
intervention_details: Prescribed article and advised fish.
- symptom_name: Hepatotoxicity
onset_date: '2025-02-08'
severity: Life-threatening
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed health and advised two.
- symptom_name: Maculopapular Rash
onset_date: '2025-02-08'
severity: Mild
outcome: Fatal
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Negative dechallenge
reporting_facility: Flores, Petersen and Lin Medical Center
reporter_type: Pharmacist
notes: Risk school condition because five. Painting coach inside sign fall. Key drug
discussion structure debate these.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-841
Date of Submission: 2025-07-23
This report was submitted by a Nurse from Morrow, Bennett and Brown Medical Center concerning patient ANON-PX-1137. The subject is a 41-year-old male with a significant medical history including atrial fibrillation, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Gabapentin administered via the Topical route at a dosage of 199mg, initiated on 2025-05-12 for Neuropathic pain with the course ongoing.
On approximately 2025-05-31, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Maculopapular Rash, Diarrhea, Stevens-Johnson syndrome, Angioedema. The Hepatotoxicity was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed simply and advised you. The current patient status regarding this symptom is 'Not Recovered'. The Maculopapular Rash was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Diarrhea was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Stevens-Johnson syndrome was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Angioedema was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-841
report_date: '2025-07-23'
patient_details:
patient_id: ANON-PX-1137
gender: Male
relevant_history:
- atrial fibrillation
- type 2 diabetes
age_at_reaction: 41
suspected_drugs:
- drug_name: Gabapentin
dosage: 199mg
route_of_administration: Topical
start_date: '2025-05-12'
indication_for_use: Neuropathic pain
adverse_reactions:
- symptom_name: Hepatotoxicity
onset_date: '2025-05-31'
severity: Severe
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed simply and advised you.
- symptom_name: Maculopapular Rash
onset_date: '2025-05-31'
severity: Moderate
outcome: Unknown
intervention_required: false
- symptom_name: Diarrhea
onset_date: '2025-05-31'
severity: Mild
outcome: Unknown
intervention_required: false
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-05-31'
severity: Mild
outcome: Not Recovered
intervention_required: false
- symptom_name: Angioedema
onset_date: '2025-05-31'
severity: Severe
outcome: Not Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 1
reporting_facility: Morrow, Bennett and Brown Medical Center
reporter_type: Nurse
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-307
Date of Submission: 2025-07-16
This report was submitted by a Other Healthcare Professional from Mckinney, Hall and Ruiz Medical Center concerning patient ANON-PX-2929. The subject is an adult female with a significant medical history including chronic kidney disease, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Warfarin administered via the Intravenous route at a dosage of 371mg, initiated on 2025-05-28 for Thromboembolism prevention and discontinued on 2025-06-27.
On approximately 2025-06-04, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Stevens-Johnson syndrome, Angioedema, Dizziness. The Vomiting was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed who and advised reflect. The current patient status regarding this symptom is 'Recovering'. The Stevens-Johnson syndrome was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed figure and advised successful. The current patient status regarding this symptom is 'Fatal'. The Angioedema was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed parent and advised interview. The current patient status regarding this symptom is 'Not Recovered'. The Dizziness was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed sense and advised research. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 7 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Blood season indicate right modern identify necessary. Try like capital knowledge. Matter own determine television appear.</data>
|
report_id: ADR-2025-307
report_date: '2025-07-16'
patient_details:
patient_id: ANON-PX-2929
gender: Female
relevant_history:
- chronic kidney disease
- type 2 diabetes
suspected_drugs:
- drug_name: Warfarin
dosage: 371mg
route_of_administration: Intravenous
start_date: '2025-05-28'
indication_for_use: Thromboembolism prevention
end_date: '2025-06-27'
adverse_reactions:
- symptom_name: Vomiting
onset_date: '2025-06-04'
severity: Life-threatening
outcome: Recovering
intervention_required: true
intervention_details: Prescribed who and advised reflect.
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-06-04'
severity: Life-threatening
outcome: Fatal
intervention_required: true
intervention_details: Prescribed figure and advised successful.
- symptom_name: Angioedema
onset_date: '2025-06-04'
severity: Mild
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed parent and advised interview.
- symptom_name: Dizziness
onset_date: '2025-06-04'
severity: Moderate
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed sense and advised research.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 7
reporting_facility: Mckinney, Hall and Ruiz Medical Center
reporter_type: Other Healthcare Professional
notes: Blood season indicate right modern identify necessary. Try like capital knowledge.
Matter own determine television appear.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-693
Date of Submission: 2025-01-01
This report was submitted by a Patient from Mcdonald PLC Medical Center concerning patient ANON-PX-6278. The subject is an adult male with a significant medical history including chronic kidney disease, migraines, seasonal allergies, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Lisinopril (ACE inhibitor) administered via the Oral route at a dosage of 197mg, initiated on 2024-10-18 for Hypertension and discontinued on 2024-12-29.
On approximately 2024-12-04, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Hepatotoxicity, Pruritus, Anaphylaxis, Diarrhea. The Dizziness was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Hepatotoxicity was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Pruritus was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Anaphylaxis was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Diarrhea was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 8 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Alone fall line number heart last goal. Stop feeling take. As hundred shoulder.</data>
|
report_id: ADR-2025-693
report_date: '2025-01-01'
patient_details:
patient_id: ANON-PX-6278
gender: Male
relevant_history:
- chronic kidney disease
- migraines
- seasonal allergies
- type 2 diabetes
suspected_drugs:
- drug_name: Lisinopril
dosage: 197mg
route_of_administration: Oral
start_date: '2024-10-18'
indication_for_use: Hypertension
drug_class: ACE inhibitor
end_date: '2024-12-29'
adverse_reactions:
- symptom_name: Dizziness
onset_date: '2024-12-04'
severity: Mild
outcome: Recovering
intervention_required: false
- symptom_name: Hepatotoxicity
onset_date: '2024-12-04'
severity: Moderate
outcome: Fatal
intervention_required: false
- symptom_name: Pruritus
onset_date: '2024-12-04'
severity: Moderate
outcome: Not Recovered
intervention_required: false
- symptom_name: Anaphylaxis
onset_date: '2024-12-04'
severity: Moderate
outcome: Fatal
intervention_required: false
- symptom_name: Diarrhea
onset_date: '2024-12-04'
severity: Severe
outcome: Recovered
intervention_required: true
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 8
reporting_facility: Mcdonald PLC Medical Center
reporter_type: Patient
notes: Alone fall line number heart last goal. Stop feeling take. As hundred shoulder.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-558
Date of Submission: 2024-12-29
This report was submitted by a Nurse from Miller, Garcia and Ramirez Medical Center concerning patient ANON-PX-8120. The subject is an adult male with a significant medical history including osteoarthritis, chronic kidney disease, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Sertraline administered via the Subcutaneous route at a dosage of 13mg, initiated on 2024-11-08 for Major depressive disorder and discontinued on 2024-12-25; Ibuprofen (NSAID) administered via the Oral route at a dosage of 156mg, initiated on 2024-11-08 for Pain and inflammation and discontinued on 2024-12-25.
On approximately 2024-12-19, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Hepatotoxicity, Nausea, Maculopapular Rash. The Headache was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Hepatotoxicity was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed field and advised else. The current patient status regarding this symptom is 'Fatal'. The Nausea was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Maculopapular Rash was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed hotel and advised others. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-558
report_date: '2024-12-29'
patient_details:
patient_id: ANON-PX-8120
gender: Male
relevant_history:
- osteoarthritis
- chronic kidney disease
- migraines
suspected_drugs:
- drug_name: Sertraline
dosage: 13mg
route_of_administration: Subcutaneous
start_date: '2024-11-08'
indication_for_use: Major depressive disorder
end_date: '2024-12-25'
- drug_name: Ibuprofen
dosage: 156mg
route_of_administration: Oral
start_date: '2024-11-08'
indication_for_use: Pain and inflammation
drug_class: NSAID
end_date: '2024-12-25'
adverse_reactions:
- symptom_name: Headache
onset_date: '2024-12-19'
severity: Severe
outcome: Unknown
intervention_required: true
- symptom_name: Hepatotoxicity
onset_date: '2024-12-19'
severity: Moderate
outcome: Fatal
intervention_required: true
intervention_details: Prescribed field and advised else.
- symptom_name: Nausea
onset_date: '2024-12-19'
severity: Moderate
outcome: Recovering
intervention_required: false
- symptom_name: Maculopapular Rash
onset_date: '2024-12-19'
severity: Moderate
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed hotel and advised others.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 6
reporting_facility: Miller, Garcia and Ramirez Medical Center
reporter_type: Nurse
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-644
Date of Submission: 2025-07-27
This report was submitted by a Patient from Williams and Sons Medical Center concerning patient ANON-PX-6339. The subject is a 76-year-old female with a significant medical history including coronary artery disease, atrial fibrillation, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Amoxicillin (Penicillin antibiotic) administered via the Intravenous route at a dosage of 483mg, initiated on 2025-05-15 for Bacterial infection and discontinued on 2025-07-15; Warfarin (Anticoagulant) administered via the Topical route at a dosage of 13mg, initiated on 2025-05-15 for Thromboembolism prevention and discontinued on 2025-07-15.
On approximately 2025-07-05, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Hepatotoxicity, Vomiting, Angioedema, Dizziness. The Maculopapular Rash was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed already and advised forget. The current patient status regarding this symptom is 'Fatal'. The Hepatotoxicity was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Vomiting was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Angioedema was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Dizziness was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 3 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Of with network make once attack base. Woman home law have. Big place whole may. Single man tree.</data>
|
report_id: ADR-2025-644
report_date: '2025-07-27'
patient_details:
patient_id: ANON-PX-6339
gender: Female
relevant_history:
- coronary artery disease
- atrial fibrillation
- osteoarthritis
age_at_reaction: 76
suspected_drugs:
- drug_name: Amoxicillin
dosage: 483mg
route_of_administration: Intravenous
start_date: '2025-05-15'
indication_for_use: Bacterial infection
drug_class: Penicillin antibiotic
end_date: '2025-07-15'
- drug_name: Warfarin
dosage: 13mg
route_of_administration: Topical
start_date: '2025-05-15'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
end_date: '2025-07-15'
adverse_reactions:
- symptom_name: Maculopapular Rash
onset_date: '2025-07-05'
severity: Life-threatening
outcome: Fatal
intervention_required: true
intervention_details: Prescribed already and advised forget.
- symptom_name: Hepatotoxicity
onset_date: '2025-07-05'
severity: Severe
outcome: Fatal
intervention_required: false
- symptom_name: Vomiting
onset_date: '2025-07-05'
severity: Life-threatening
outcome: Unknown
intervention_required: false
- symptom_name: Angioedema
onset_date: '2025-07-05'
severity: Severe
outcome: Recovering
intervention_required: false
- symptom_name: Dizziness
onset_date: '2025-07-05'
severity: Severe
outcome: Fatal
intervention_required: false
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 3
reporting_facility: Williams and Sons Medical Center
reporter_type: Patient
notes: Of with network make once attack base. Woman home law have. Big place whole
may. Single man tree.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-854
Date of Submission: 2025-01-10
This report was submitted by a Patient from Phillips Inc Medical Center concerning patient ANON-PX-3476. The subject is a 27-year-old other with a significant medical history including anxiety, type 2 diabetes, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Lisinopril (ACE inhibitor) administered via the Subcutaneous route at a dosage of 7mg, initiated on 2024-10-19 for Hypertension with the course ongoing; Gabapentin (Anticonvulsant) administered via the Intravenous route at a dosage of 327mg, initiated on 2024-10-19 for Neuropathic pain with the course ongoing.
On approximately 2024-12-13, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Headache. The Dizziness was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed order and advised drive. The current patient status regarding this symptom is 'Recovered'. The Headache was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Number available teacher by. Direction much example. Live get especially send senior effect.</data>
|
report_id: ADR-2025-854
report_date: '2025-01-10'
patient_details:
patient_id: ANON-PX-3476
gender: Other
relevant_history:
- anxiety
- type 2 diabetes
- atrial fibrillation
age_at_reaction: 27
suspected_drugs:
- drug_name: Lisinopril
dosage: 7mg
route_of_administration: Subcutaneous
start_date: '2024-10-19'
indication_for_use: Hypertension
drug_class: ACE inhibitor
- drug_name: Gabapentin
dosage: 327mg
route_of_administration: Intravenous
start_date: '2024-10-19'
indication_for_use: Neuropathic pain
drug_class: Anticonvulsant
adverse_reactions:
- symptom_name: Dizziness
onset_date: '2024-12-13'
severity: Severe
outcome: Recovered
intervention_required: true
intervention_details: Prescribed order and advised drive.
- symptom_name: Headache
onset_date: '2024-12-13'
severity: Life-threatening
outcome: Unknown
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive rechallenge
reporting_facility: Phillips Inc Medical Center
reporter_type: Patient
notes: Number available teacher by. Direction much example. Live get especially send
senior effect.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-261
Date of Submission: 2024-12-07
This report was submitted by a Other Healthcare Professional from Taylor and Sons Medical Center concerning patient ANON-PX-8796. The subject is a 60-year-old male with a significant medical history including type 2 diabetes, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Lisinopril administered via the Subcutaneous route at a dosage of 188mg, initiated on 2024-10-16 for Hypertension with the course ongoing.
On approximately 2024-10-27, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Nausea, Hepatotoxicity, Angioedema, Diarrhea, Somnolence. The Nausea was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed art and advised magazine. The current patient status regarding this symptom is 'Fatal'. The Hepatotoxicity was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed dark and advised when. The current patient status regarding this symptom is 'Unknown'. The Angioedema was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Diarrhea was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Somnolence was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Bar sing have success gas follow. Ball wind Republican family age than.</data>
|
report_id: ADR-2024-261
report_date: '2024-12-07'
patient_details:
patient_id: ANON-PX-8796
gender: Male
relevant_history:
- type 2 diabetes
- asthma
age_at_reaction: 60
suspected_drugs:
- drug_name: Lisinopril
dosage: 188mg
route_of_administration: Subcutaneous
start_date: '2024-10-16'
indication_for_use: Hypertension
adverse_reactions:
- symptom_name: Nausea
onset_date: '2024-10-27'
severity: Life-threatening
outcome: Fatal
intervention_required: true
intervention_details: Prescribed art and advised magazine.
- symptom_name: Hepatotoxicity
onset_date: '2024-10-27'
severity: Mild
outcome: Unknown
intervention_required: true
intervention_details: Prescribed dark and advised when.
- symptom_name: Angioedema
onset_date: '2024-10-27'
severity: Life-threatening
outcome: Recovering
intervention_required: false
- symptom_name: Diarrhea
onset_date: '2024-10-27'
severity: Life-threatening
outcome: Unknown
intervention_required: false
- symptom_name: Somnolence
onset_date: '2024-10-27'
severity: Life-threatening
outcome: Unknown
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive dechallenge
reporting_facility: Taylor and Sons Medical Center
reporter_type: Other Healthcare Professional
notes: Bar sing have success gas follow. Ball wind Republican family age than.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-745
Date of Submission: 2025-03-09
This report was submitted by a Physician from Mcgee-Fernandez Medical Center concerning patient ANON-PX-7819. The subject is an adult male with a significant medical history including migraines, hypertension, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Atorvastatin (Statin) administered via the Subcutaneous route at a dosage of 206mg, initiated on 2025-02-23 for Hypercholesterolemia with the course ongoing.
On approximately 2025-02-26, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Stevens-Johnson syndrome, Headache. The Anaphylaxis was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed benefit and advised poor. The current patient status regarding this symptom is 'Fatal'. The Stevens-Johnson syndrome was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed really and advised five. The current patient status regarding this symptom is 'Not Recovered'. The Headache was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed little and advised cut. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 9 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Once law crime challenge one by certain. News sound grow prepare my. Radio different care easy security building.</data>
|
report_id: ADR-2025-745
report_date: '2025-03-09'
patient_details:
patient_id: ANON-PX-7819
gender: Male
relevant_history:
- migraines
- hypertension
- seasonal allergies
suspected_drugs:
- drug_name: Atorvastatin
dosage: 206mg
route_of_administration: Subcutaneous
start_date: '2025-02-23'
indication_for_use: Hypercholesterolemia
drug_class: Statin
adverse_reactions:
- symptom_name: Anaphylaxis
onset_date: '2025-02-26'
severity: Severe
outcome: Fatal
intervention_required: true
intervention_details: Prescribed benefit and advised poor.
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-02-26'
severity: Severe
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed really and advised five.
- symptom_name: Headache
onset_date: '2025-02-26'
severity: Moderate
outcome: Unknown
intervention_required: true
intervention_details: Prescribed little and advised cut.
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 9
reporting_facility: Mcgee-Fernandez Medical Center
reporter_type: Physician
notes: Once law crime challenge one by certain. News sound grow prepare my. Radio
different care easy security building.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-217
Date of Submission: 2025-04-15
This report was submitted by a Patient from Fowler-Wilson Medical Center concerning patient ANON-PX-9918. The subject is a 78-year-old male with a significant medical history including asthma, migraines, anxiety, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Oral route at a dosage of 432mg, initiated on 2025-02-06 for Pain and inflammation with the course ongoing.
On approximately 2025-03-17, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Diarrhea, Anaphylaxis, Headache. The Maculopapular Rash was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed space and advised several. The current patient status regarding this symptom is 'Unknown'. The Diarrhea was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed official and advised kitchen. The current patient status regarding this symptom is 'Recovering'. The Anaphylaxis was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Headache was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 7 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-217
report_date: '2025-04-15'
patient_details:
patient_id: ANON-PX-9918
gender: Male
relevant_history:
- asthma
- migraines
- anxiety
- chronic kidney disease
age_at_reaction: 78
suspected_drugs:
- drug_name: Ibuprofen
dosage: 432mg
route_of_administration: Oral
start_date: '2025-02-06'
indication_for_use: Pain and inflammation
drug_class: NSAID
adverse_reactions:
- symptom_name: Maculopapular Rash
onset_date: '2025-03-17'
severity: Moderate
outcome: Unknown
intervention_required: true
intervention_details: Prescribed space and advised several.
- symptom_name: Diarrhea
onset_date: '2025-03-17'
severity: Severe
outcome: Recovering
intervention_required: true
intervention_details: Prescribed official and advised kitchen.
- symptom_name: Anaphylaxis
onset_date: '2025-03-17'
severity: Moderate
outcome: Unknown
intervention_required: false
- symptom_name: Headache
onset_date: '2025-03-17'
severity: Life-threatening
outcome: Recovering
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 7
reporting_facility: Fowler-Wilson Medical Center
reporter_type: Patient
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-305
Date of Submission: 2025-06-28
This report was submitted by a Other Healthcare Professional from Holmes, Avila and Long Medical Center concerning patient ANON-PX-8879. The subject is an adult male with a significant medical history including chronic kidney disease, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Oral route at a dosage of 299mg, initiated on 2025-05-15 for Hypothyroidism with the course ongoing.
On approximately 2025-06-09, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Angioedema, Anaphylaxis. The Angioedema was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Anaphylaxis was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 8 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-305
report_date: '2025-06-28'
patient_details:
patient_id: ANON-PX-8879
gender: Male
relevant_history:
- chronic kidney disease
- coronary artery disease
suspected_drugs:
- drug_name: Levothyroxine
dosage: 299mg
route_of_administration: Oral
start_date: '2025-05-15'
indication_for_use: Hypothyroidism
drug_class: Thyroid hormone
adverse_reactions:
- symptom_name: Angioedema
onset_date: '2025-06-09'
severity: Life-threatening
outcome: Unknown
intervention_required: false
- symptom_name: Anaphylaxis
onset_date: '2025-06-09'
severity: Mild
outcome: Unknown
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 8
reporting_facility: Holmes, Avila and Long Medical Center
reporter_type: Other Healthcare Professional
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-764
Date of Submission: 2025-08-05
This report was submitted by a Nurse from Arroyo-Figueroa Medical Center concerning patient ANON-PX-4113. The subject is a 54-year-old female with a significant medical history including type 2 diabetes, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Amoxicillin (Penicillin antibiotic) administered via the Oral route at a dosage of 425mg, initiated on 2025-07-15 for Bacterial infection and discontinued on 2025-08-04.
On approximately 2025-08-02, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Angioedema. The Vomiting was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Angioedema was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed listen and advised middle. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 10 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-764
report_date: '2025-08-05'
patient_details:
patient_id: ANON-PX-4113
gender: Female
relevant_history:
- type 2 diabetes
- chronic kidney disease
age_at_reaction: 54
suspected_drugs:
- drug_name: Amoxicillin
dosage: 425mg
route_of_administration: Oral
start_date: '2025-07-15'
indication_for_use: Bacterial infection
drug_class: Penicillin antibiotic
end_date: '2025-08-04'
adverse_reactions:
- symptom_name: Vomiting
onset_date: '2025-08-02'
severity: Life-threatening
outcome: Unknown
intervention_required: true
- symptom_name: Angioedema
onset_date: '2025-08-02'
severity: Mild
outcome: Recovering
intervention_required: true
intervention_details: Prescribed listen and advised middle.
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Not applicable
naranjo_score: 10
reporting_facility: Arroyo-Figueroa Medical Center
reporter_type: Nurse
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-914
Date of Submission: 2024-11-02
This report was submitted by a Patient from Reyes, Gross and Robinson Medical Center concerning patient ANON-PX-8697. The subject is a 63-year-old other with a significant medical history including atrial fibrillation, osteoarthritis, coronary artery disease, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Omeprazole administered via the Intravenous route at a dosage of 330mg, initiated on 2024-09-14 for Gastroesophageal reflux disease and discontinued on 2024-10-09; Amoxicillin (Penicillin antibiotic) administered via the Intramuscular route at a dosage of 314mg, initiated on 2024-09-14 for Bacterial infection and discontinued on 2024-10-09.
On approximately 2024-09-25, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Angioedema, Vomiting. The Angioedema was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed spring and advised really. The current patient status regarding this symptom is 'Fatal'. The Vomiting was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 7 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: The over skill first. With perform she. Process memory suffer hotel send office conference.</data>
|
report_id: ADR-2024-914
report_date: '2024-11-02'
patient_details:
patient_id: ANON-PX-8697
gender: Other
relevant_history:
- atrial fibrillation
- osteoarthritis
- coronary artery disease
- hypertension
age_at_reaction: 63
suspected_drugs:
- drug_name: Omeprazole
dosage: 330mg
route_of_administration: Intravenous
start_date: '2024-09-14'
indication_for_use: Gastroesophageal reflux disease
end_date: '2024-10-09'
- drug_name: Amoxicillin
dosage: 314mg
route_of_administration: Intramuscular
start_date: '2024-09-14'
indication_for_use: Bacterial infection
drug_class: Penicillin antibiotic
end_date: '2024-10-09'
adverse_reactions:
- symptom_name: Angioedema
onset_date: '2024-09-25'
severity: Life-threatening
outcome: Fatal
intervention_required: true
intervention_details: Prescribed spring and advised really.
- symptom_name: Vomiting
onset_date: '2024-09-25'
severity: Severe
outcome: Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 7
reporting_facility: Reyes, Gross and Robinson Medical Center
reporter_type: Patient
notes: The over skill first. With perform she. Process memory suffer hotel send office
conference.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-338
Date of Submission: 2025-02-10
This report was submitted by a Nurse from Lane, Mckinney and Riddle Medical Center concerning patient ANON-PX-6561. The subject is a 41-year-old other with a significant medical history including atrial fibrillation, type 2 diabetes, coronary artery disease, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Amoxicillin (Penicillin antibiotic) administered via the Oral route at a dosage of 377mg, initiated on 2025-01-13 for Bacterial infection with the course ongoing.
On approximately 2025-01-20, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Nausea, Headache, Diarrhea, Pruritus. The Anaphylaxis was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Nausea was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Headache was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Diarrhea was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Pruritus was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Risk take support. Her out begin instead. Federal check reduce.</data>
|
report_id: ADR-2025-338
report_date: '2025-02-10'
patient_details:
patient_id: ANON-PX-6561
gender: Other
relevant_history:
- atrial fibrillation
- type 2 diabetes
- coronary artery disease
- hypertension
age_at_reaction: 41
suspected_drugs:
- drug_name: Amoxicillin
dosage: 377mg
route_of_administration: Oral
start_date: '2025-01-13'
indication_for_use: Bacterial infection
drug_class: Penicillin antibiotic
adverse_reactions:
- symptom_name: Anaphylaxis
onset_date: '2025-01-20'
severity: Mild
outcome: Recovering
intervention_required: false
- symptom_name: Nausea
onset_date: '2025-01-20'
severity: Mild
outcome: Recovering
intervention_required: false
- symptom_name: Headache
onset_date: '2025-01-20'
severity: Mild
outcome: Recovering
intervention_required: false
- symptom_name: Diarrhea
onset_date: '2025-01-20'
severity: Severe
outcome: Fatal
intervention_required: false
- symptom_name: Pruritus
onset_date: '2025-01-20'
severity: Life-threatening
outcome: Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 6
reporting_facility: Lane, Mckinney and Riddle Medical Center
reporter_type: Nurse
notes: Risk take support. Her out begin instead. Federal check reduce.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-361
Date of Submission: 2024-12-15
This report was submitted by a Other Healthcare Professional from Lee, Daniels and Miller Medical Center concerning patient ANON-PX-5391. The subject is a 52-year-old male with a significant medical history including migraines, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Omeprazole (Proton-pump inhibitor) administered via the Topical route at a dosage of 188mg, initiated on 2024-09-29 for Gastroesophageal reflux disease and discontinued on 2024-11-27; Ibuprofen (NSAID) administered via the Oral route at a dosage of 405mg, initiated on 2024-09-29 for Pain and inflammation and discontinued on 2024-11-27.
On approximately 2024-11-23, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Hepatotoxicity. The Maculopapular Rash was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. The Hepatotoxicity was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 10 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Not give position end media discover condition according. You real dinner.</data>
|
report_id: ADR-2024-361
report_date: '2024-12-15'
patient_details:
patient_id: ANON-PX-5391
gender: Male
relevant_history:
- migraines
- type 2 diabetes
age_at_reaction: 52
suspected_drugs:
- drug_name: Omeprazole
dosage: 188mg
route_of_administration: Topical
start_date: '2024-09-29'
indication_for_use: Gastroesophageal reflux disease
drug_class: Proton-pump inhibitor
end_date: '2024-11-27'
- drug_name: Ibuprofen
dosage: 405mg
route_of_administration: Oral
start_date: '2024-09-29'
indication_for_use: Pain and inflammation
drug_class: NSAID
end_date: '2024-11-27'
adverse_reactions:
- symptom_name: Maculopapular Rash
onset_date: '2024-11-23'
severity: Life-threatening
outcome: Fatal
intervention_required: true
- symptom_name: Hepatotoxicity
onset_date: '2024-11-23'
severity: Mild
outcome: Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 10
reporting_facility: Lee, Daniels and Miller Medical Center
reporter_type: Other Healthcare Professional
notes: Not give position end media discover condition according. You real dinner.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-393
Date of Submission: 2024-10-06
This report was submitted by a Nurse from Harris-Taylor Medical Center concerning patient ANON-PX-8320. The subject is a 32-year-old female with a significant medical history including hypertension, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Topical route at a dosage of 59mg, initiated on 2024-08-02 for Pain and inflammation and discontinued on 2024-09-17; Amoxicillin (Penicillin antibiotic) administered via the Intravenous route at a dosage of 167mg, initiated on 2024-08-02 for Bacterial infection and discontinued on 2024-09-17.
On approximately 2024-09-17, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Angioedema. The Dizziness was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Angioedema was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 9 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-393
report_date: '2024-10-06'
patient_details:
patient_id: ANON-PX-8320
gender: Female
relevant_history:
- hypertension
- type 2 diabetes
age_at_reaction: 32
suspected_drugs:
- drug_name: Ibuprofen
dosage: 59mg
route_of_administration: Topical
start_date: '2024-08-02'
indication_for_use: Pain and inflammation
drug_class: NSAID
end_date: '2024-09-17'
- drug_name: Amoxicillin
dosage: 167mg
route_of_administration: Intravenous
start_date: '2024-08-02'
indication_for_use: Bacterial infection
drug_class: Penicillin antibiotic
end_date: '2024-09-17'
adverse_reactions:
- symptom_name: Dizziness
onset_date: '2024-09-17'
severity: Life-threatening
outcome: Recovering
intervention_required: false
- symptom_name: Angioedema
onset_date: '2024-09-17'
severity: Mild
outcome: Fatal
intervention_required: false
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 9
reporting_facility: Harris-Taylor Medical Center
reporter_type: Nurse
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-464
Date of Submission: 2024-09-13
This report was submitted by a Physician from Thompson, Summers and Monroe Medical Center concerning patient ANON-PX-2411. The subject is a 54-year-old other with a significant medical history including type 2 diabetes, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Omeprazole (Proton-pump inhibitor) administered via the Oral route at a dosage of 397mg, initiated on 2024-08-31 for Gastroesophageal reflux disease and discontinued on 2024-09-08; Atorvastatin (Statin) administered via the Topical route at a dosage of 215mg, initiated on 2024-08-31 for Hypercholesterolemia and discontinued on 2024-09-08.
On approximately 2024-09-05, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Vomiting. The Dizziness was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Vomiting was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed trial and advised car. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 3 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Professional participant nothing than outside from after. Behind there air look. Seek listen other yes everything several.</data>
|
report_id: ADR-2024-464
report_date: '2024-09-13'
patient_details:
patient_id: ANON-PX-2411
gender: Other
relevant_history:
- type 2 diabetes
- hypertension
age_at_reaction: 54
suspected_drugs:
- drug_name: Omeprazole
dosage: 397mg
route_of_administration: Oral
start_date: '2024-08-31'
indication_for_use: Gastroesophageal reflux disease
drug_class: Proton-pump inhibitor
end_date: '2024-09-08'
- drug_name: Atorvastatin
dosage: 215mg
route_of_administration: Topical
start_date: '2024-08-31'
indication_for_use: Hypercholesterolemia
drug_class: Statin
end_date: '2024-09-08'
adverse_reactions:
- symptom_name: Dizziness
onset_date: '2024-09-05'
severity: Moderate
outcome: Unknown
intervention_required: true
- symptom_name: Vomiting
onset_date: '2024-09-05'
severity: Life-threatening
outcome: Unknown
intervention_required: true
intervention_details: Prescribed trial and advised car.
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 3
reporting_facility: Thompson, Summers and Monroe Medical Center
reporter_type: Physician
notes: Professional participant nothing than outside from after. Behind there air
look. Seek listen other yes everything several.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-299
Date of Submission: 2025-04-14
This report was submitted by a Pharmacist from Wright, Hood and Silva Medical Center concerning patient ANON-PX-6597. The subject is a 78-year-old male with a significant medical history including asthma, anxiety, seasonal allergies, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Topical route at a dosage of 433mg, initiated on 2025-01-19 for Pain and inflammation and discontinued on 2025-04-12; Warfarin (Anticoagulant) administered via the Intramuscular route at a dosage of 61mg, initiated on 2025-01-19 for Thromboembolism prevention and discontinued on 2025-04-12.
On approximately 2025-04-12, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Diarrhea, Anaphylaxis, Stevens-Johnson syndrome, Pruritus. The Vomiting was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Diarrhea was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed quickly and advised build. The current patient status regarding this symptom is 'Not Recovered'. The Anaphylaxis was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Stevens-Johnson syndrome was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Pruritus was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 10 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Whose trade product away administration hot evidence. Appear someone PM see factor. Management best quality difference behavior crime civil. Picture away miss point.</data>
|
report_id: ADR-2025-299
report_date: '2025-04-14'
patient_details:
patient_id: ANON-PX-6597
gender: Male
relevant_history:
- asthma
- anxiety
- seasonal allergies
- type 2 diabetes
age_at_reaction: 78
suspected_drugs:
- drug_name: Ibuprofen
dosage: 433mg
route_of_administration: Topical
start_date: '2025-01-19'
indication_for_use: Pain and inflammation
drug_class: NSAID
end_date: '2025-04-12'
- drug_name: Warfarin
dosage: 61mg
route_of_administration: Intramuscular
start_date: '2025-01-19'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
end_date: '2025-04-12'
adverse_reactions:
- symptom_name: Vomiting
onset_date: '2025-04-12'
severity: Life-threatening
outcome: Recovered
intervention_required: false
- symptom_name: Diarrhea
onset_date: '2025-04-12'
severity: Mild
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed quickly and advised build.
- symptom_name: Anaphylaxis
onset_date: '2025-04-12'
severity: Mild
outcome: Not Recovered
intervention_required: false
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-04-12'
severity: Severe
outcome: Recovered
intervention_required: false
- symptom_name: Pruritus
onset_date: '2025-04-12'
severity: Life-threatening
outcome: Fatal
intervention_required: false
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 10
reporting_facility: Wright, Hood and Silva Medical Center
reporter_type: Pharmacist
notes: Whose trade product away administration hot evidence. Appear someone PM see
factor. Management best quality difference behavior crime civil. Picture away miss
point.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-662
Date of Submission: 2024-09-16
This report was submitted by a Other Healthcare Professional from Strickland, Palmer and Hall Medical Center concerning patient ANON-PX-3764. The subject is a 40-year-old other with a significant medical history including migraines, atrial fibrillation, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Atorvastatin (Statin) administered via the Intravenous route at a dosage of 302mg, initiated on 2024-08-26 for Hypercholesterolemia with the course ongoing; Warfarin (Anticoagulant) administered via the Intramuscular route at a dosage of 194mg, initiated on 2024-08-26 for Thromboembolism prevention with the course ongoing.
On approximately 2024-09-12, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Dizziness. The Maculopapular Rash was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'. The Dizziness was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 8 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-662
report_date: '2024-09-16'
patient_details:
patient_id: ANON-PX-3764
gender: Other
relevant_history:
- migraines
- atrial fibrillation
- seasonal allergies
age_at_reaction: 40
suspected_drugs:
- drug_name: Atorvastatin
dosage: 302mg
route_of_administration: Intravenous
start_date: '2024-08-26'
indication_for_use: Hypercholesterolemia
drug_class: Statin
- drug_name: Warfarin
dosage: 194mg
route_of_administration: Intramuscular
start_date: '2024-08-26'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
adverse_reactions:
- symptom_name: Maculopapular Rash
onset_date: '2024-09-12'
severity: Severe
outcome: Not Recovered
intervention_required: true
- symptom_name: Dizziness
onset_date: '2024-09-12'
severity: Severe
outcome: Recovering
intervention_required: true
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 8
reporting_facility: Strickland, Palmer and Hall Medical Center
reporter_type: Other Healthcare Professional
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-461
Date of Submission: 2025-01-16
This report was submitted by a Physician from Garcia-Woods Medical Center concerning patient ANON-PX-9386. The subject is a 33-year-old other with a significant medical history including chronic kidney disease, hypertension, coronary artery disease, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Topical route at a dosage of 397mg, initiated on 2024-11-02 for Neuropathic pain and discontinued on 2024-12-12; Levothyroxine (Thyroid hormone) administered via the Intramuscular route at a dosage of 41mg, initiated on 2024-11-02 for Hypothyroidism and discontinued on 2024-12-12.
On approximately 2024-12-09, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Diarrhea, Somnolence. The Headache was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Diarrhea was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Somnolence was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed explain and advised area. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 9 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Purpose meet necessary worker serve. Between one budget country development office. Debate edge represent too situation make suffer.</data>
|
report_id: ADR-2025-461
report_date: '2025-01-16'
patient_details:
patient_id: ANON-PX-9386
gender: Other
relevant_history:
- chronic kidney disease
- hypertension
- coronary artery disease
- atrial fibrillation
age_at_reaction: 33
suspected_drugs:
- drug_name: Gabapentin
dosage: 397mg
route_of_administration: Topical
start_date: '2024-11-02'
indication_for_use: Neuropathic pain
drug_class: Anticonvulsant
end_date: '2024-12-12'
- drug_name: Levothyroxine
dosage: 41mg
route_of_administration: Intramuscular
start_date: '2024-11-02'
indication_for_use: Hypothyroidism
drug_class: Thyroid hormone
end_date: '2024-12-12'
adverse_reactions:
- symptom_name: Headache
onset_date: '2024-12-09'
severity: Moderate
outcome: Fatal
intervention_required: false
- symptom_name: Diarrhea
onset_date: '2024-12-09'
severity: Moderate
outcome: Fatal
intervention_required: false
- symptom_name: Somnolence
onset_date: '2024-12-09'
severity: Mild
outcome: Recovered
intervention_required: true
intervention_details: Prescribed explain and advised area.
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 9
reporting_facility: Garcia-Woods Medical Center
reporter_type: Physician
notes: Purpose meet necessary worker serve. Between one budget country development
office. Debate edge represent too situation make suffer.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-760
Date of Submission: 2025-07-23
This report was submitted by a Pharmacist from Jones-Wagner Medical Center concerning patient ANON-PX-4231. The subject is a 32-year-old other with a significant medical history including chronic kidney disease, anxiety, migraines, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Omeprazole (Proton-pump inhibitor) administered via the Intravenous route at a dosage of 65mg, initiated on 2025-06-29 for Gastroesophageal reflux disease and discontinued on 2025-07-21; Metformin administered via the Subcutaneous route at a dosage of 293mg, initiated on 2025-06-29 for Type 2 diabetes and discontinued on 2025-07-21.
On approximately 2025-07-16, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Headache. The Anaphylaxis was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed relationship and advised product. The current patient status regarding this symptom is 'Recovering'. The Headache was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed Mrs and advised whatever. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Seem million director new a. Unit their contain situation skill. Above design few computer.</data>
|
report_id: ADR-2025-760
report_date: '2025-07-23'
patient_details:
patient_id: ANON-PX-4231
gender: Other
relevant_history:
- chronic kidney disease
- anxiety
- migraines
- asthma
age_at_reaction: 32
suspected_drugs:
- drug_name: Omeprazole
dosage: 65mg
route_of_administration: Intravenous
start_date: '2025-06-29'
indication_for_use: Gastroesophageal reflux disease
drug_class: Proton-pump inhibitor
end_date: '2025-07-21'
- drug_name: Metformin
dosage: 293mg
route_of_administration: Subcutaneous
start_date: '2025-06-29'
indication_for_use: Type 2 diabetes
end_date: '2025-07-21'
adverse_reactions:
- symptom_name: Anaphylaxis
onset_date: '2025-07-16'
severity: Life-threatening
outcome: Recovering
intervention_required: true
intervention_details: Prescribed relationship and advised product.
- symptom_name: Headache
onset_date: '2025-07-16'
severity: Severe
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed Mrs and advised whatever.
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 1
reporting_facility: Jones-Wagner Medical Center
reporter_type: Pharmacist
notes: Seem million director new a. Unit their contain situation skill. Above design
few computer.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-119
Date of Submission: 2025-07-27
This report was submitted by a Nurse from Henderson, Acevedo and Smith Medical Center concerning patient ANON-PX-1231. The subject is a 62-year-old other with a significant medical history including migraines, coronary artery disease, anxiety, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Oral route at a dosage of 247mg, initiated on 2025-04-28 for Pain and inflammation and discontinued on 2025-07-18; Sertraline (SSRI) administered via the Subcutaneous route at a dosage of 157mg, initiated on 2025-04-28 for Major depressive disorder and discontinued on 2025-07-18.
On approximately 2025-05-10, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Headache, Hepatotoxicity, Dizziness. The Stevens-Johnson syndrome was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed food and advised would. The current patient status regarding this symptom is 'Unknown'. The Headache was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed leave and advised still. The current patient status regarding this symptom is 'Recovered'. The Hepatotoxicity was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Dizziness was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed focus and advised admit. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 9 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Get person a offer college. Structure truth power himself.</data>
|
report_id: ADR-2025-119
report_date: '2025-07-27'
patient_details:
patient_id: ANON-PX-1231
gender: Other
relevant_history:
- migraines
- coronary artery disease
- anxiety
- osteoarthritis
age_at_reaction: 62
suspected_drugs:
- drug_name: Ibuprofen
dosage: 247mg
route_of_administration: Oral
start_date: '2025-04-28'
indication_for_use: Pain and inflammation
drug_class: NSAID
end_date: '2025-07-18'
- drug_name: Sertraline
dosage: 157mg
route_of_administration: Subcutaneous
start_date: '2025-04-28'
indication_for_use: Major depressive disorder
drug_class: SSRI
end_date: '2025-07-18'
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-05-10'
severity: Life-threatening
outcome: Unknown
intervention_required: true
intervention_details: Prescribed food and advised would.
- symptom_name: Headache
onset_date: '2025-05-10'
severity: Mild
outcome: Recovered
intervention_required: true
intervention_details: Prescribed leave and advised still.
- symptom_name: Hepatotoxicity
onset_date: '2025-05-10'
severity: Severe
outcome: Recovered
intervention_required: false
- symptom_name: Dizziness
onset_date: '2025-05-10'
severity: Severe
outcome: Recovering
intervention_required: true
intervention_details: Prescribed focus and advised admit.
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 9
reporting_facility: Henderson, Acevedo and Smith Medical Center
reporter_type: Nurse
notes: Get person a offer college. Structure truth power himself.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-265
Date of Submission: 2025-06-14
This report was submitted by a Physician from Mcdaniel-Gonzalez Medical Center concerning patient ANON-PX-6026. The subject is a 55-year-old male with a significant medical history including coronary artery disease, migraines, atrial fibrillation, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Sertraline (SSRI) administered via the Intravenous route at a dosage of 300mg, initiated on 2025-04-19 for Major depressive disorder and discontinued on 2025-06-09.
On approximately 2025-06-01, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Angioedema, Headache. The Stevens-Johnson syndrome was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Angioedema was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Headache was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 8 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-265
report_date: '2025-06-14'
patient_details:
patient_id: ANON-PX-6026
gender: Male
relevant_history:
- coronary artery disease
- migraines
- atrial fibrillation
- anxiety
age_at_reaction: 55
suspected_drugs:
- drug_name: Sertraline
dosage: 300mg
route_of_administration: Intravenous
start_date: '2025-04-19'
indication_for_use: Major depressive disorder
drug_class: SSRI
end_date: '2025-06-09'
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-06-01'
severity: Severe
outcome: Fatal
intervention_required: false
- symptom_name: Angioedema
onset_date: '2025-06-01'
severity: Mild
outcome: Recovered
intervention_required: false
- symptom_name: Headache
onset_date: '2025-06-01'
severity: Moderate
outcome: Not Recovered
intervention_required: true
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 8
reporting_facility: Mcdaniel-Gonzalez Medical Center
reporter_type: Physician
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-856
Date of Submission: 2024-08-13
This report was submitted by a Patient from Miller, Hernandez and Abbott Medical Center concerning patient ANON-PX-4399. The subject is a 77-year-old female with a significant medical history including anxiety, chronic kidney disease, type 2 diabetes, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Omeprazole (Proton-pump inhibitor) administered via the Oral route at a dosage of 430mg, initiated on 2024-06-12 for Gastroesophageal reflux disease and discontinued on 2024-08-11.
On approximately 2024-08-07, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Maculopapular Rash, Somnolence. The Stevens-Johnson syndrome was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed attention and advised phone. The current patient status regarding this symptom is 'Unknown'. The Maculopapular Rash was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Somnolence was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 7 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Rise window after tell game design. Big whom lead natural send sing time. Current never then include measure visit.</data>
|
report_id: ADR-2024-856
report_date: '2024-08-13'
patient_details:
patient_id: ANON-PX-4399
gender: Female
relevant_history:
- anxiety
- chronic kidney disease
- type 2 diabetes
- coronary artery disease
age_at_reaction: 77
suspected_drugs:
- drug_name: Omeprazole
dosage: 430mg
route_of_administration: Oral
start_date: '2024-06-12'
indication_for_use: Gastroesophageal reflux disease
drug_class: Proton-pump inhibitor
end_date: '2024-08-11'
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-08-07'
severity: Severe
outcome: Unknown
intervention_required: true
intervention_details: Prescribed attention and advised phone.
- symptom_name: Maculopapular Rash
onset_date: '2024-08-07'
severity: Mild
outcome: Unknown
intervention_required: false
- symptom_name: Somnolence
onset_date: '2024-08-07'
severity: Life-threatening
outcome: Unknown
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 7
reporting_facility: Miller, Hernandez and Abbott Medical Center
reporter_type: Patient
notes: Rise window after tell game design. Big whom lead natural send sing time. Current
never then include measure visit.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-284
Date of Submission: 2025-08-02
This report was submitted by a Patient from Davis, Lyons and Palmer Medical Center concerning patient ANON-PX-9449. The subject is an adult male with a significant medical history including migraines, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Omeprazole (Proton-pump inhibitor) administered via the Intravenous route at a dosage of 445mg, initiated on 2025-06-01 for Gastroesophageal reflux disease and discontinued on 2025-07-29.
On approximately 2025-07-26, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Pruritus, Diarrhea, Maculopapular Rash, Nausea. The Anaphylaxis was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Pruritus was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Diarrhea was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Maculopapular Rash was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Nausea was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Talk compare determine raise instead. Create voice every camera at sense edge.</data>
|
report_id: ADR-2025-284
report_date: '2025-08-02'
patient_details:
patient_id: ANON-PX-9449
gender: Male
relevant_history:
- migraines
- atrial fibrillation
suspected_drugs:
- drug_name: Omeprazole
dosage: 445mg
route_of_administration: Intravenous
start_date: '2025-06-01'
indication_for_use: Gastroesophageal reflux disease
drug_class: Proton-pump inhibitor
end_date: '2025-07-29'
adverse_reactions:
- symptom_name: Anaphylaxis
onset_date: '2025-07-26'
severity: Life-threatening
outcome: Recovered
intervention_required: false
- symptom_name: Pruritus
onset_date: '2025-07-26'
severity: Mild
outcome: Recovering
intervention_required: false
- symptom_name: Diarrhea
onset_date: '2025-07-26'
severity: Life-threatening
outcome: Fatal
intervention_required: false
- symptom_name: Maculopapular Rash
onset_date: '2025-07-26'
severity: Moderate
outcome: Unknown
intervention_required: false
- symptom_name: Nausea
onset_date: '2025-07-26'
severity: Moderate
outcome: Unknown
intervention_required: true
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive rechallenge
reporting_facility: Davis, Lyons and Palmer Medical Center
reporter_type: Patient
notes: Talk compare determine raise instead. Create voice every camera at sense edge.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-944
Date of Submission: 2025-07-25
This report was submitted by a Pharmacist from Miller PLC Medical Center concerning patient ANON-PX-5340. The subject is an adult male with a significant medical history including asthma, hypertension, osteoarthritis, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Lisinopril administered via the Oral route at a dosage of 326mg, initiated on 2025-06-07 for Hypertension and discontinued on 2025-07-13.
On approximately 2025-06-27, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Diarrhea, Anaphylaxis. The Diarrhea was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Anaphylaxis was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Thank maintain involve east really political. Nice probably wall get baby star investment computer. With meet idea.</data>
|
report_id: ADR-2025-944
report_date: '2025-07-25'
patient_details:
patient_id: ANON-PX-5340
gender: Male
relevant_history:
- asthma
- hypertension
- osteoarthritis
- migraines
suspected_drugs:
- drug_name: Lisinopril
dosage: 326mg
route_of_administration: Oral
start_date: '2025-06-07'
indication_for_use: Hypertension
end_date: '2025-07-13'
adverse_reactions:
- symptom_name: Diarrhea
onset_date: '2025-06-27'
severity: Life-threatening
outcome: Fatal
intervention_required: false
- symptom_name: Anaphylaxis
onset_date: '2025-06-27'
severity: Mild
outcome: Recovering
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Not applicable
reporting_facility: Miller PLC Medical Center
reporter_type: Pharmacist
notes: Thank maintain involve east really political. Nice probably wall get baby star
investment computer. With meet idea.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-111
Date of Submission: 2025-03-14
This report was submitted by a Patient from Mitchell, Mann and Kelley Medical Center concerning patient ANON-PX-4278. The subject is a 55-year-old other with a significant medical history including seasonal allergies, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Warfarin (Anticoagulant) administered via the Intravenous route at a dosage of 246mg, initiated on 2024-12-30 for Thromboembolism prevention and discontinued on 2025-03-06.
On approximately 2025-02-28, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Nausea, Angioedema, Headache. The Nausea was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Angioedema was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Headache was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Modern later specific something. Perhaps large test sport range or because.</data>
|
report_id: ADR-2025-111
report_date: '2025-03-14'
patient_details:
patient_id: ANON-PX-4278
gender: Other
relevant_history:
- seasonal allergies
- asthma
age_at_reaction: 55
suspected_drugs:
- drug_name: Warfarin
dosage: 246mg
route_of_administration: Intravenous
start_date: '2024-12-30'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
end_date: '2025-03-06'
adverse_reactions:
- symptom_name: Nausea
onset_date: '2025-02-28'
severity: Mild
outcome: Unknown
intervention_required: false
- symptom_name: Angioedema
onset_date: '2025-02-28'
severity: Life-threatening
outcome: Recovering
intervention_required: false
- symptom_name: Headache
onset_date: '2025-02-28'
severity: Mild
outcome: Not Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Rechallenge not performed
reporting_facility: Mitchell, Mann and Kelley Medical Center
reporter_type: Patient
notes: Modern later specific something. Perhaps large test sport range or because.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-316
Date of Submission: 2024-09-08
This report was submitted by a Other Healthcare Professional from Allen and Sons Medical Center concerning patient ANON-PX-4672. The subject is a 68-year-old other with a significant medical history including migraines, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Warfarin (Anticoagulant) administered via the Subcutaneous route at a dosage of 297mg, initiated on 2024-06-14 for Thromboembolism prevention and discontinued on 2024-09-05; Atorvastatin (Statin) administered via the Intravenous route at a dosage of 444mg, initiated on 2024-06-14 for Hypercholesterolemia and discontinued on 2024-09-05.
On approximately 2024-08-22, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Somnolence, Anaphylaxis, Nausea. The Hepatotoxicity was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed science and advised job. The current patient status regarding this symptom is 'Unknown'. The Somnolence was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed put and advised also. The current patient status regarding this symptom is 'Recovering'. The Anaphylaxis was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovering'. The Nausea was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Share song beat sell large nor. Me feel office head soon sit arm. Pick hope far measure someone must.</data>
|
report_id: ADR-2024-316
report_date: '2024-09-08'
patient_details:
patient_id: ANON-PX-4672
gender: Other
relevant_history:
- migraines
- asthma
age_at_reaction: 68
suspected_drugs:
- drug_name: Warfarin
dosage: 297mg
route_of_administration: Subcutaneous
start_date: '2024-06-14'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
end_date: '2024-09-05'
- drug_name: Atorvastatin
dosage: 444mg
route_of_administration: Intravenous
start_date: '2024-06-14'
indication_for_use: Hypercholesterolemia
drug_class: Statin
end_date: '2024-09-05'
adverse_reactions:
- symptom_name: Hepatotoxicity
onset_date: '2024-08-22'
severity: Life-threatening
outcome: Unknown
intervention_required: true
intervention_details: Prescribed science and advised job.
- symptom_name: Somnolence
onset_date: '2024-08-22'
severity: Severe
outcome: Recovering
intervention_required: true
intervention_details: Prescribed put and advised also.
- symptom_name: Anaphylaxis
onset_date: '2024-08-22'
severity: Life-threatening
outcome: Recovering
intervention_required: true
- symptom_name: Nausea
onset_date: '2024-08-22'
severity: Severe
outcome: Not Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 5
reporting_facility: Allen and Sons Medical Center
reporter_type: Other Healthcare Professional
notes: Share song beat sell large nor. Me feel office head soon sit arm. Pick hope
far measure someone must.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-656
Date of Submission: 2024-12-13
This report was submitted by a Nurse from White-Huffman Medical Center concerning patient ANON-PX-6861. The subject is a 86-year-old female with a significant medical history including osteoarthritis, seasonal allergies, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Subcutaneous route at a dosage of 372mg, initiated on 2024-11-18 for Hypothyroidism and discontinued on 2024-11-27.
On approximately 2024-11-24, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Dizziness, Somnolence. The Maculopapular Rash was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed he and advised hard. The current patient status regarding this symptom is 'Fatal'. The Dizziness was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Somnolence was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed same and advised let. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 2 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-656
report_date: '2024-12-13'
patient_details:
patient_id: ANON-PX-6861
gender: Female
relevant_history:
- osteoarthritis
- seasonal allergies
- hypertension
age_at_reaction: 86
suspected_drugs:
- drug_name: Levothyroxine
dosage: 372mg
route_of_administration: Subcutaneous
start_date: '2024-11-18'
indication_for_use: Hypothyroidism
drug_class: Thyroid hormone
end_date: '2024-11-27'
adverse_reactions:
- symptom_name: Maculopapular Rash
onset_date: '2024-11-24'
severity: Life-threatening
outcome: Fatal
intervention_required: true
intervention_details: Prescribed he and advised hard.
- symptom_name: Dizziness
onset_date: '2024-11-24'
severity: Mild
outcome: Not Recovered
intervention_required: false
- symptom_name: Somnolence
onset_date: '2024-11-24'
severity: Moderate
outcome: Recovered
intervention_required: true
intervention_details: Prescribed same and advised let.
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 2
reporting_facility: White-Huffman Medical Center
reporter_type: Nurse
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-478
Date of Submission: 2025-03-09
This report was submitted by a Nurse from Kim Inc Medical Center concerning patient ANON-PX-2899. The subject is an adult male with a significant medical history including anxiety, hypertension, atrial fibrillation, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Warfarin (Anticoagulant) administered via the Topical route at a dosage of 60mg, initiated on 2024-12-23 for Thromboembolism prevention and discontinued on 2025-01-28.
On approximately 2025-01-03, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Stevens-Johnson syndrome. The Vomiting was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed economy and advised west. The current patient status regarding this symptom is 'Fatal'. The Stevens-Johnson syndrome was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed place and advised country. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 7 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-478
report_date: '2025-03-09'
patient_details:
patient_id: ANON-PX-2899
gender: Male
relevant_history:
- anxiety
- hypertension
- atrial fibrillation
- type 2 diabetes
suspected_drugs:
- drug_name: Warfarin
dosage: 60mg
route_of_administration: Topical
start_date: '2024-12-23'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
end_date: '2025-01-28'
adverse_reactions:
- symptom_name: Vomiting
onset_date: '2025-01-03'
severity: Mild
outcome: Fatal
intervention_required: true
intervention_details: Prescribed economy and advised west.
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-01-03'
severity: Moderate
outcome: Recovered
intervention_required: true
intervention_details: Prescribed place and advised country.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 7
reporting_facility: Kim Inc Medical Center
reporter_type: Nurse
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-685
Date of Submission: 2025-08-12
This report was submitted by a Pharmacist from Mendez-Taylor Medical Center concerning patient ANON-PX-4767. The subject is a 75-year-old female with a significant medical history including anxiety, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Lisinopril administered via the Intravenous route at a dosage of 140mg, initiated on 2025-07-26 for Hypertension with the course ongoing; Amoxicillin (Penicillin antibiotic) administered via the Subcutaneous route at a dosage of 325mg, initiated on 2025-07-26 for Bacterial infection with the course ongoing.
On approximately 2025-08-06, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Pruritus, Angioedema, Stevens-Johnson syndrome. The Headache was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Pruritus was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Angioedema was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Stevens-Johnson syndrome was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Window fight dream what.</data>
|
report_id: ADR-2025-685
report_date: '2025-08-12'
patient_details:
patient_id: ANON-PX-4767
gender: Female
relevant_history:
- anxiety
- coronary artery disease
age_at_reaction: 75
suspected_drugs:
- drug_name: Lisinopril
dosage: 140mg
route_of_administration: Intravenous
start_date: '2025-07-26'
indication_for_use: Hypertension
- drug_name: Amoxicillin
dosage: 325mg
route_of_administration: Subcutaneous
start_date: '2025-07-26'
indication_for_use: Bacterial infection
drug_class: Penicillin antibiotic
adverse_reactions:
- symptom_name: Headache
onset_date: '2025-08-06'
severity: Moderate
outcome: Not Recovered
intervention_required: false
- symptom_name: Pruritus
onset_date: '2025-08-06'
severity: Mild
outcome: Not Recovered
intervention_required: false
- symptom_name: Angioedema
onset_date: '2025-08-06'
severity: Moderate
outcome: Fatal
intervention_required: false
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-08-06'
severity: Mild
outcome: Fatal
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 5
reporting_facility: Mendez-Taylor Medical Center
reporter_type: Pharmacist
notes: Window fight dream what.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-284
Date of Submission: 2025-04-23
This report was submitted by a Physician from Moore, Perry and Gray Medical Center concerning patient ANON-PX-7772. The subject is an adult other with a significant medical history including seasonal allergies, coronary artery disease, anxiety, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Atorvastatin administered via the Intravenous route at a dosage of 77mg, initiated on 2025-03-08 for Hypercholesterolemia with the course ongoing; Omeprazole (Proton-pump inhibitor) administered via the Intramuscular route at a dosage of 192mg, initiated on 2025-03-08 for Gastroesophageal reflux disease with the course ongoing.
On approximately 2025-03-30, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Headache. The Vomiting was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed you and advised lay. The current patient status regarding this symptom is 'Fatal'. The Headache was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed fear and advised everyone. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Often lay step enough cold water dog development. Alone outside imagine sister crime.</data>
|
report_id: ADR-2025-284
report_date: '2025-04-23'
patient_details:
patient_id: ANON-PX-7772
gender: Other
relevant_history:
- seasonal allergies
- coronary artery disease
- anxiety
- osteoarthritis
suspected_drugs:
- drug_name: Atorvastatin
dosage: 77mg
route_of_administration: Intravenous
start_date: '2025-03-08'
indication_for_use: Hypercholesterolemia
- drug_name: Omeprazole
dosage: 192mg
route_of_administration: Intramuscular
start_date: '2025-03-08'
indication_for_use: Gastroesophageal reflux disease
drug_class: Proton-pump inhibitor
adverse_reactions:
- symptom_name: Vomiting
onset_date: '2025-03-30'
severity: Life-threatening
outcome: Fatal
intervention_required: true
intervention_details: Prescribed you and advised lay.
- symptom_name: Headache
onset_date: '2025-03-30'
severity: Life-threatening
outcome: Fatal
intervention_required: true
intervention_details: Prescribed fear and advised everyone.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive rechallenge
reporting_facility: Moore, Perry and Gray Medical Center
reporter_type: Physician
notes: Often lay step enough cold water dog development. Alone outside imagine sister
crime.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-858
Date of Submission: 2025-03-10
This report was submitted by a Nurse from Brooks Ltd Medical Center concerning patient ANON-PX-9576. The subject is a 77-year-old male with a significant medical history including chronic kidney disease, type 2 diabetes, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Atorvastatin (Statin) administered via the Intravenous route at a dosage of 161mg, initiated on 2025-02-27 for Hypercholesterolemia and discontinued on 2025-03-04; Warfarin (Anticoagulant) administered via the Oral route at a dosage of 53mg, initiated on 2025-02-27 for Thromboembolism prevention and discontinued on 2025-03-04.
On approximately 2025-03-03, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Somnolence, Anaphylaxis, Angioedema. The Somnolence was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'. The Anaphylaxis was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Angioedema was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Hair pretty everybody forget. Less guess drive newspaper. Fear edge table degree this light Mrs.</data>
|
report_id: ADR-2025-858
report_date: '2025-03-10'
patient_details:
patient_id: ANON-PX-9576
gender: Male
relevant_history:
- chronic kidney disease
- type 2 diabetes
- coronary artery disease
age_at_reaction: 77
suspected_drugs:
- drug_name: Atorvastatin
dosage: 161mg
route_of_administration: Intravenous
start_date: '2025-02-27'
indication_for_use: Hypercholesterolemia
drug_class: Statin
end_date: '2025-03-04'
- drug_name: Warfarin
dosage: 53mg
route_of_administration: Oral
start_date: '2025-02-27'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
end_date: '2025-03-04'
adverse_reactions:
- symptom_name: Somnolence
onset_date: '2025-03-03'
severity: Life-threatening
outcome: Not Recovered
intervention_required: true
- symptom_name: Anaphylaxis
onset_date: '2025-03-03'
severity: Mild
outcome: Unknown
intervention_required: false
- symptom_name: Angioedema
onset_date: '2025-03-03'
severity: Moderate
outcome: Unknown
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Negative dechallenge
reporting_facility: Brooks Ltd Medical Center
reporter_type: Nurse
notes: Hair pretty everybody forget. Less guess drive newspaper. Fear edge table degree
this light Mrs.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-560
Date of Submission: 2024-10-24
This report was submitted by a Patient from Wilson-Ross Medical Center concerning patient ANON-PX-8175. The subject is a 51-year-old female with a significant medical history including type 2 diabetes, osteoarthritis, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Omeprazole administered via the Topical route at a dosage of 234mg, initiated on 2024-08-22 for Gastroesophageal reflux disease and discontinued on 2024-10-12; Warfarin (Anticoagulant) administered via the Intravenous route at a dosage of 343mg, initiated on 2024-08-22 for Thromboembolism prevention and discontinued on 2024-10-12.
On approximately 2024-09-14, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Nausea, Angioedema, Vomiting. The Dizziness was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Nausea was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed be and advised factor. The current patient status regarding this symptom is 'Recovered'. The Angioedema was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Vomiting was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed build and advised ago. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-560
report_date: '2024-10-24'
patient_details:
patient_id: ANON-PX-8175
gender: Female
relevant_history:
- type 2 diabetes
- osteoarthritis
- hypertension
age_at_reaction: 51
suspected_drugs:
- drug_name: Omeprazole
dosage: 234mg
route_of_administration: Topical
start_date: '2024-08-22'
indication_for_use: Gastroesophageal reflux disease
end_date: '2024-10-12'
- drug_name: Warfarin
dosage: 343mg
route_of_administration: Intravenous
start_date: '2024-08-22'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
end_date: '2024-10-12'
adverse_reactions:
- symptom_name: Dizziness
onset_date: '2024-09-14'
severity: Mild
outcome: Fatal
intervention_required: false
- symptom_name: Nausea
onset_date: '2024-09-14'
severity: Life-threatening
outcome: Recovered
intervention_required: true
intervention_details: Prescribed be and advised factor.
- symptom_name: Angioedema
onset_date: '2024-09-14'
severity: Moderate
outcome: Fatal
intervention_required: false
- symptom_name: Vomiting
onset_date: '2024-09-14'
severity: Severe
outcome: Fatal
intervention_required: true
intervention_details: Prescribed build and advised ago.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 6
reporting_facility: Wilson-Ross Medical Center
reporter_type: Patient
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-478
Date of Submission: 2024-08-28
This report was submitted by a Physician from Torres and Sons Medical Center concerning patient ANON-PX-7326. The subject is an adult male with a significant medical history including hypertension, osteoarthritis, type 2 diabetes, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Oral route at a dosage of 370mg, initiated on 2024-06-28 for Neuropathic pain and discontinued on 2024-08-24.
On approximately 2024-08-16, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Hepatotoxicity, Nausea, Stevens-Johnson syndrome, Somnolence. The Anaphylaxis was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Hepatotoxicity was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Nausea was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Stevens-Johnson syndrome was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Somnolence was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed realize and advised off. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-478
report_date: '2024-08-28'
patient_details:
patient_id: ANON-PX-7326
gender: Male
relevant_history:
- hypertension
- osteoarthritis
- type 2 diabetes
- migraines
suspected_drugs:
- drug_name: Gabapentin
dosage: 370mg
route_of_administration: Oral
start_date: '2024-06-28'
indication_for_use: Neuropathic pain
drug_class: Anticonvulsant
end_date: '2024-08-24'
adverse_reactions:
- symptom_name: Anaphylaxis
onset_date: '2024-08-16'
severity: Life-threatening
outcome: Not Recovered
intervention_required: false
- symptom_name: Hepatotoxicity
onset_date: '2024-08-16'
severity: Life-threatening
outcome: Fatal
intervention_required: false
- symptom_name: Nausea
onset_date: '2024-08-16'
severity: Mild
outcome: Unknown
intervention_required: false
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-08-16'
severity: Life-threatening
outcome: Not Recovered
intervention_required: false
- symptom_name: Somnolence
onset_date: '2024-08-16'
severity: Mild
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed realize and advised off.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive dechallenge
reporting_facility: Torres and Sons Medical Center
reporter_type: Physician
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-953
Date of Submission: 2025-05-29
This report was submitted by a Physician from Lee, Jordan and Hill Medical Center concerning patient ANON-PX-5149. The subject is a 69-year-old male with a significant medical history including type 2 diabetes, anxiety, coronary artery disease, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Intramuscular route at a dosage of 299mg, initiated on 2025-04-04 for Pain and inflammation and discontinued on 2025-05-26; Atorvastatin administered via the Topical route at a dosage of 411mg, initiated on 2025-04-04 for Hypercholesterolemia and discontinued on 2025-05-26.
On approximately 2025-05-22, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Pruritus, Nausea. The Vomiting was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Pruritus was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Nausea was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 9 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Identify future act partner continue. Environmental game war reach good blue. Choose grow participant value whole him oil.</data>
|
report_id: ADR-2025-953
report_date: '2025-05-29'
patient_details:
patient_id: ANON-PX-5149
gender: Male
relevant_history:
- type 2 diabetes
- anxiety
- coronary artery disease
- osteoarthritis
age_at_reaction: 69
suspected_drugs:
- drug_name: Ibuprofen
dosage: 299mg
route_of_administration: Intramuscular
start_date: '2025-04-04'
indication_for_use: Pain and inflammation
drug_class: NSAID
end_date: '2025-05-26'
- drug_name: Atorvastatin
dosage: 411mg
route_of_administration: Topical
start_date: '2025-04-04'
indication_for_use: Hypercholesterolemia
end_date: '2025-05-26'
adverse_reactions:
- symptom_name: Vomiting
onset_date: '2025-05-22'
severity: Severe
outcome: Fatal
intervention_required: false
- symptom_name: Pruritus
onset_date: '2025-05-22'
severity: Life-threatening
outcome: Not Recovered
intervention_required: false
- symptom_name: Nausea
onset_date: '2025-05-22'
severity: Life-threatening
outcome: Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 9
reporting_facility: Lee, Jordan and Hill Medical Center
reporter_type: Physician
notes: Identify future act partner continue. Environmental game war reach good blue.
Choose grow participant value whole him oil.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-803
Date of Submission: 2025-03-07
This report was submitted by a Pharmacist from Williams, Scott and Rodriguez Medical Center concerning patient ANON-PX-9552. The subject is a 71-year-old female with a significant medical history including atrial fibrillation, osteoarthritis, coronary artery disease, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Atorvastatin (Statin) administered via the Intramuscular route at a dosage of 264mg, initiated on 2024-12-23 for Hypercholesterolemia and discontinued on 2025-03-03; Warfarin (Anticoagulant) administered via the Oral route at a dosage of 127mg, initiated on 2024-12-23 for Thromboembolism prevention and discontinued on 2025-03-03.
On approximately 2025-02-10, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Angioedema, Nausea, Pruritus, Headache. The Angioedema was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Nausea was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Pruritus was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed appear and advised city. The current patient status regarding this symptom is 'Not Recovered'. The Headache was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: So range time that fund player political. Star during goal husband develop.</data>
|
report_id: ADR-2025-803
report_date: '2025-03-07'
patient_details:
patient_id: ANON-PX-9552
gender: Female
relevant_history:
- atrial fibrillation
- osteoarthritis
- coronary artery disease
- migraines
age_at_reaction: 71
suspected_drugs:
- drug_name: Atorvastatin
dosage: 264mg
route_of_administration: Intramuscular
start_date: '2024-12-23'
indication_for_use: Hypercholesterolemia
drug_class: Statin
end_date: '2025-03-03'
- drug_name: Warfarin
dosage: 127mg
route_of_administration: Oral
start_date: '2024-12-23'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
end_date: '2025-03-03'
adverse_reactions:
- symptom_name: Angioedema
onset_date: '2025-02-10'
severity: Moderate
outcome: Unknown
intervention_required: true
- symptom_name: Nausea
onset_date: '2025-02-10'
severity: Severe
outcome: Unknown
intervention_required: true
- symptom_name: Pruritus
onset_date: '2025-02-10'
severity: Life-threatening
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed appear and advised city.
- symptom_name: Headache
onset_date: '2025-02-10'
severity: Life-threatening
outcome: Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Not applicable
reporting_facility: Williams, Scott and Rodriguez Medical Center
reporter_type: Pharmacist
notes: So range time that fund player political. Star during goal husband develop.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-838
Date of Submission: 2025-01-14
This report was submitted by a Other Healthcare Professional from Harris, Garcia and Castillo Medical Center concerning patient ANON-PX-5975. The subject is an adult male with a significant medical history including osteoarthritis, seasonal allergies, type 2 diabetes, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Sertraline (SSRI) administered via the Intravenous route at a dosage of 487mg, initiated on 2024-10-21 for Major depressive disorder and discontinued on 2025-01-02; Metformin (Biguanide) administered via the Oral route at a dosage of 156mg, initiated on 2024-10-21 for Type 2 diabetes and discontinued on 2025-01-02.
On approximately 2024-10-30, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Nausea, Vomiting, Stevens-Johnson syndrome. The Headache was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Nausea was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed my and advised must. The current patient status regarding this symptom is 'Not Recovered'. The Vomiting was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Stevens-Johnson syndrome was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-838
report_date: '2025-01-14'
patient_details:
patient_id: ANON-PX-5975
gender: Male
relevant_history:
- osteoarthritis
- seasonal allergies
- type 2 diabetes
- coronary artery disease
suspected_drugs:
- drug_name: Sertraline
dosage: 487mg
route_of_administration: Intravenous
start_date: '2024-10-21'
indication_for_use: Major depressive disorder
drug_class: SSRI
end_date: '2025-01-02'
- drug_name: Metformin
dosage: 156mg
route_of_administration: Oral
start_date: '2024-10-21'
indication_for_use: Type 2 diabetes
drug_class: Biguanide
end_date: '2025-01-02'
adverse_reactions:
- symptom_name: Headache
onset_date: '2024-10-30'
severity: Life-threatening
outcome: Recovered
intervention_required: true
- symptom_name: Nausea
onset_date: '2024-10-30'
severity: Moderate
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed my and advised must.
- symptom_name: Vomiting
onset_date: '2024-10-30'
severity: Moderate
outcome: Recovering
intervention_required: false
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-10-30'
severity: Moderate
outcome: Unknown
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive dechallenge
reporting_facility: Harris, Garcia and Castillo Medical Center
reporter_type: Other Healthcare Professional
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-505
Date of Submission: 2024-11-20
This report was submitted by a Physician from Roberts-Schneider Medical Center concerning patient ANON-PX-9217. The subject is a 58-year-old female with a significant medical history including asthma, migraines, type 2 diabetes, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Metformin administered via the Intramuscular route at a dosage of 152mg, initiated on 2024-10-29 for Type 2 diabetes and discontinued on 2024-11-13.
On approximately 2024-11-07, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Diarrhea, Stevens-Johnson syndrome. The Diarrhea was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Stevens-Johnson syndrome was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed above and advised hotel. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 8 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-505
report_date: '2024-11-20'
patient_details:
patient_id: ANON-PX-9217
gender: Female
relevant_history:
- asthma
- migraines
- type 2 diabetes
- hypertension
age_at_reaction: 58
suspected_drugs:
- drug_name: Metformin
dosage: 152mg
route_of_administration: Intramuscular
start_date: '2024-10-29'
indication_for_use: Type 2 diabetes
end_date: '2024-11-13'
adverse_reactions:
- symptom_name: Diarrhea
onset_date: '2024-11-07'
severity: Moderate
outcome: Recovered
intervention_required: false
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-11-07'
severity: Severe
outcome: Recovering
intervention_required: true
intervention_details: Prescribed above and advised hotel.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 8
reporting_facility: Roberts-Schneider Medical Center
reporter_type: Physician
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-116
Date of Submission: 2024-11-04
This report was submitted by a Physician from Keller-Fields Medical Center concerning patient ANON-PX-3167. The subject is a 55-year-old male with a significant medical history including seasonal allergies, migraines, type 2 diabetes, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Topical route at a dosage of 430mg, initiated on 2024-08-30 for Hypothyroidism with the course ongoing; Sertraline administered via the Oral route at a dosage of 350mg, initiated on 2024-08-30 for Major depressive disorder with the course ongoing.
On approximately 2024-10-05, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Hepatotoxicity, Pruritus, Stevens-Johnson syndrome, Headache. The Maculopapular Rash was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed important and advised own. The current patient status regarding this symptom is 'Fatal'. The Hepatotoxicity was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed finally and advised central. The current patient status regarding this symptom is 'Recovered'. The Pruritus was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Stevens-Johnson syndrome was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Headache was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 3 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-116
report_date: '2024-11-04'
patient_details:
patient_id: ANON-PX-3167
gender: Male
relevant_history:
- seasonal allergies
- migraines
- type 2 diabetes
- hypertension
age_at_reaction: 55
suspected_drugs:
- drug_name: Levothyroxine
dosage: 430mg
route_of_administration: Topical
start_date: '2024-08-30'
indication_for_use: Hypothyroidism
drug_class: Thyroid hormone
- drug_name: Sertraline
dosage: 350mg
route_of_administration: Oral
start_date: '2024-08-30'
indication_for_use: Major depressive disorder
adverse_reactions:
- symptom_name: Maculopapular Rash
onset_date: '2024-10-05'
severity: Moderate
outcome: Fatal
intervention_required: true
intervention_details: Prescribed important and advised own.
- symptom_name: Hepatotoxicity
onset_date: '2024-10-05'
severity: Life-threatening
outcome: Recovered
intervention_required: true
intervention_details: Prescribed finally and advised central.
- symptom_name: Pruritus
onset_date: '2024-10-05'
severity: Moderate
outcome: Recovered
intervention_required: true
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-10-05'
severity: Mild
outcome: Fatal
intervention_required: false
- symptom_name: Headache
onset_date: '2024-10-05'
severity: Moderate
outcome: Recovering
intervention_required: true
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 3
reporting_facility: Keller-Fields Medical Center
reporter_type: Physician
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-520
Date of Submission: 2025-03-17
This report was submitted by a Nurse from Martin-York Medical Center concerning patient ANON-PX-3489. The subject is a 72-year-old other with a significant medical history including coronary artery disease, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Topical route at a dosage of 473mg, initiated on 2025-02-09 for Neuropathic pain and discontinued on 2025-02-25.
On approximately 2025-02-25, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Pruritus, Headache. The Pruritus was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed wide and advised yes. The current patient status regarding this symptom is 'Recovered'. The Headache was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed current and advised among. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 7 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-520
report_date: '2025-03-17'
patient_details:
patient_id: ANON-PX-3489
gender: Other
relevant_history:
- coronary artery disease
- atrial fibrillation
age_at_reaction: 72
suspected_drugs:
- drug_name: Gabapentin
dosage: 473mg
route_of_administration: Topical
start_date: '2025-02-09'
indication_for_use: Neuropathic pain
drug_class: Anticonvulsant
end_date: '2025-02-25'
adverse_reactions:
- symptom_name: Pruritus
onset_date: '2025-02-25'
severity: Moderate
outcome: Recovered
intervention_required: true
intervention_details: Prescribed wide and advised yes.
- symptom_name: Headache
onset_date: '2025-02-25'
severity: Severe
outcome: Unknown
intervention_required: true
intervention_details: Prescribed current and advised among.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 7
reporting_facility: Martin-York Medical Center
reporter_type: Nurse
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-525
Date of Submission: 2025-07-22
This report was submitted by a Other Healthcare Professional from Taylor, Marquez and Sampson Medical Center concerning patient ANON-PX-2235. The subject is a 46-year-old male with a significant medical history including anxiety, atrial fibrillation, coronary artery disease, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Warfarin (Anticoagulant) administered via the Oral route at a dosage of 378mg, initiated on 2025-05-21 for Thromboembolism prevention with the course ongoing.
On approximately 2025-07-04, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Diarrhea, Headache. The Dizziness was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. The Diarrhea was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Headache was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed seven and advised stand. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 8 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Couple agency newspaper professional wrong nation begin.</data>
|
report_id: ADR-2025-525
report_date: '2025-07-22'
patient_details:
patient_id: ANON-PX-2235
gender: Male
relevant_history:
- anxiety
- atrial fibrillation
- coronary artery disease
- seasonal allergies
age_at_reaction: 46
suspected_drugs:
- drug_name: Warfarin
dosage: 378mg
route_of_administration: Oral
start_date: '2025-05-21'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
adverse_reactions:
- symptom_name: Dizziness
onset_date: '2025-07-04'
severity: Severe
outcome: Fatal
intervention_required: true
- symptom_name: Diarrhea
onset_date: '2025-07-04'
severity: Moderate
outcome: Not Recovered
intervention_required: false
- symptom_name: Headache
onset_date: '2025-07-04'
severity: Moderate
outcome: Recovered
intervention_required: true
intervention_details: Prescribed seven and advised stand.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 8
reporting_facility: Taylor, Marquez and Sampson Medical Center
reporter_type: Other Healthcare Professional
notes: Couple agency newspaper professional wrong nation begin.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-410
Date of Submission: 2024-09-11
This report was submitted by a Patient from Mckinney Ltd Medical Center concerning patient ANON-PX-2762. The subject is an adult other with a significant medical history including seasonal allergies, chronic kidney disease, asthma, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Metformin administered via the Intramuscular route at a dosage of 399mg, initiated on 2024-07-08 for Type 2 diabetes with the course ongoing; Levothyroxine (Thyroid hormone) administered via the Subcutaneous route at a dosage of 32mg, initiated on 2024-07-08 for Hypothyroidism with the course ongoing.
On approximately 2024-08-21, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Nausea, Anaphylaxis. The Nausea was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed decade and advised life. The current patient status regarding this symptom is 'Fatal'. The Anaphylaxis was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed training and advised type. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Lead decade owner nice while. Window security past interesting item development positive staff.</data>
|
report_id: ADR-2024-410
report_date: '2024-09-11'
patient_details:
patient_id: ANON-PX-2762
gender: Other
relevant_history:
- seasonal allergies
- chronic kidney disease
- asthma
- osteoarthritis
suspected_drugs:
- drug_name: Metformin
dosage: 399mg
route_of_administration: Intramuscular
start_date: '2024-07-08'
indication_for_use: Type 2 diabetes
- drug_name: Levothyroxine
dosage: 32mg
route_of_administration: Subcutaneous
start_date: '2024-07-08'
indication_for_use: Hypothyroidism
drug_class: Thyroid hormone
adverse_reactions:
- symptom_name: Nausea
onset_date: '2024-08-21'
severity: Moderate
outcome: Fatal
intervention_required: true
intervention_details: Prescribed decade and advised life.
- symptom_name: Anaphylaxis
onset_date: '2024-08-21'
severity: Mild
outcome: Recovered
intervention_required: true
intervention_details: Prescribed training and advised type.
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 1
reporting_facility: Mckinney Ltd Medical Center
reporter_type: Patient
notes: Lead decade owner nice while. Window security past interesting item development
positive staff.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-202
Date of Submission: 2025-02-21
This report was submitted by a Physician from Fuller-Drake Medical Center concerning patient ANON-PX-4406. The subject is an adult female with a significant medical history including seasonal allergies, asthma, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Omeprazole (Proton-pump inhibitor) administered via the Intravenous route at a dosage of 400mg, initiated on 2024-11-24 for Gastroesophageal reflux disease and discontinued on 2025-01-18; Levothyroxine administered via the Oral route at a dosage of 444mg, initiated on 2024-11-24 for Hypothyroidism and discontinued on 2025-01-18.
On approximately 2025-01-15, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Angioedema, Diarrhea, Pruritus, Hepatotoxicity. The Vomiting was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed mission and advised laugh. The current patient status regarding this symptom is 'Recovering'. The Angioedema was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Diarrhea was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Pruritus was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Hepatotoxicity was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed feel and advised she. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Case point nice follow small citizen law provide. Drug first myself determine crime beautiful. Senior minute push range doctor go.</data>
|
report_id: ADR-2025-202
report_date: '2025-02-21'
patient_details:
patient_id: ANON-PX-4406
gender: Female
relevant_history:
- seasonal allergies
- asthma
- atrial fibrillation
suspected_drugs:
- drug_name: Omeprazole
dosage: 400mg
route_of_administration: Intravenous
start_date: '2024-11-24'
indication_for_use: Gastroesophageal reflux disease
drug_class: Proton-pump inhibitor
end_date: '2025-01-18'
- drug_name: Levothyroxine
dosage: 444mg
route_of_administration: Oral
start_date: '2024-11-24'
indication_for_use: Hypothyroidism
end_date: '2025-01-18'
adverse_reactions:
- symptom_name: Vomiting
onset_date: '2025-01-15'
severity: Mild
outcome: Recovering
intervention_required: true
intervention_details: Prescribed mission and advised laugh.
- symptom_name: Angioedema
onset_date: '2025-01-15'
severity: Life-threatening
outcome: Fatal
intervention_required: false
- symptom_name: Diarrhea
onset_date: '2025-01-15'
severity: Moderate
outcome: Recovered
intervention_required: false
- symptom_name: Pruritus
onset_date: '2025-01-15'
severity: Moderate
outcome: Fatal
intervention_required: false
- symptom_name: Hepatotoxicity
onset_date: '2025-01-15'
severity: Mild
outcome: Recovering
intervention_required: true
intervention_details: Prescribed feel and advised she.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Rechallenge not performed
reporting_facility: Fuller-Drake Medical Center
reporter_type: Physician
notes: Case point nice follow small citizen law provide. Drug first myself determine
crime beautiful. Senior minute push range doctor go.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-446
Date of Submission: 2024-08-25
This report was submitted by a Nurse from Haas Inc Medical Center concerning patient ANON-PX-8347. The subject is a 83-year-old other with a significant medical history including migraines, coronary artery disease, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Sertraline (SSRI) administered via the Subcutaneous route at a dosage of 272mg, initiated on 2024-06-02 for Major depressive disorder with the course ongoing.
On approximately 2024-08-05, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Somnolence, Nausea, Angioedema. The Vomiting was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Somnolence was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Nausea was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Angioedema was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed body and advised magazine. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 10 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-446
report_date: '2024-08-25'
patient_details:
patient_id: ANON-PX-8347
gender: Other
relevant_history:
- migraines
- coronary artery disease
- asthma
age_at_reaction: 83
suspected_drugs:
- drug_name: Sertraline
dosage: 272mg
route_of_administration: Subcutaneous
start_date: '2024-06-02'
indication_for_use: Major depressive disorder
drug_class: SSRI
adverse_reactions:
- symptom_name: Vomiting
onset_date: '2024-08-05'
severity: Severe
outcome: Unknown
intervention_required: false
- symptom_name: Somnolence
onset_date: '2024-08-05'
severity: Life-threatening
outcome: Unknown
intervention_required: false
- symptom_name: Nausea
onset_date: '2024-08-05'
severity: Severe
outcome: Not Recovered
intervention_required: false
- symptom_name: Angioedema
onset_date: '2024-08-05'
severity: Severe
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed body and advised magazine.
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 10
reporting_facility: Haas Inc Medical Center
reporter_type: Nurse
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-928
Date of Submission: 2024-12-11
This report was submitted by a Other Healthcare Professional from Wilson, Hall and Velazquez Medical Center concerning patient ANON-PX-6943. The subject is an adult other with a significant medical history including seasonal allergies, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Subcutaneous route at a dosage of 379mg, initiated on 2024-10-22 for Pain and inflammation with the course ongoing; Warfarin (Anticoagulant) administered via the Topical route at a dosage of 137mg, initiated on 2024-10-22 for Thromboembolism prevention with the course ongoing.
On approximately 2024-11-04, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Angioedema, Maculopapular Rash, Vomiting, Headache. The Anaphylaxis was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Angioedema was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed close and advised start. The current patient status regarding this symptom is 'Recovering'. The Maculopapular Rash was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Vomiting was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed figure and advised want. The current patient status regarding this symptom is 'Recovering'. The Headache was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-928
report_date: '2024-12-11'
patient_details:
patient_id: ANON-PX-6943
gender: Other
relevant_history:
- seasonal allergies
- anxiety
suspected_drugs:
- drug_name: Ibuprofen
dosage: 379mg
route_of_administration: Subcutaneous
start_date: '2024-10-22'
indication_for_use: Pain and inflammation
drug_class: NSAID
- drug_name: Warfarin
dosage: 137mg
route_of_administration: Topical
start_date: '2024-10-22'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
adverse_reactions:
- symptom_name: Anaphylaxis
onset_date: '2024-11-04'
severity: Moderate
outcome: Recovered
intervention_required: true
- symptom_name: Angioedema
onset_date: '2024-11-04'
severity: Life-threatening
outcome: Recovering
intervention_required: true
intervention_details: Prescribed close and advised start.
- symptom_name: Maculopapular Rash
onset_date: '2024-11-04'
severity: Mild
outcome: Recovered
intervention_required: false
- symptom_name: Vomiting
onset_date: '2024-11-04'
severity: Severe
outcome: Recovering
intervention_required: true
intervention_details: Prescribed figure and advised want.
- symptom_name: Headache
onset_date: '2024-11-04'
severity: Moderate
outcome: Recovering
intervention_required: true
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive dechallenge
reporting_facility: Wilson, Hall and Velazquez Medical Center
reporter_type: Other Healthcare Professional
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-776
Date of Submission: 2024-10-28
This report was submitted by a Physician from Wallace and Sons Medical Center concerning patient ANON-PX-2047. The subject is a 40-year-old female with a significant medical history including migraines, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Oral route at a dosage of 251mg, initiated on 2024-09-04 for Hypothyroidism and discontinued on 2024-10-18.
On approximately 2024-10-15, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Nausea, Anaphylaxis, Diarrhea, Vomiting. The Dizziness was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Nausea was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed thing and advised office. The current patient status regarding this symptom is 'Unknown'. The Anaphylaxis was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'. The Diarrhea was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Vomiting was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 4 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-776
report_date: '2024-10-28'
patient_details:
patient_id: ANON-PX-2047
gender: Female
relevant_history:
- migraines
- seasonal allergies
age_at_reaction: 40
suspected_drugs:
- drug_name: Levothyroxine
dosage: 251mg
route_of_administration: Oral
start_date: '2024-09-04'
indication_for_use: Hypothyroidism
drug_class: Thyroid hormone
end_date: '2024-10-18'
adverse_reactions:
- symptom_name: Dizziness
onset_date: '2024-10-15'
severity: Mild
outcome: Unknown
intervention_required: true
- symptom_name: Nausea
onset_date: '2024-10-15'
severity: Mild
outcome: Unknown
intervention_required: true
intervention_details: Prescribed thing and advised office.
- symptom_name: Anaphylaxis
onset_date: '2024-10-15'
severity: Moderate
outcome: Not Recovered
intervention_required: true
- symptom_name: Diarrhea
onset_date: '2024-10-15'
severity: Mild
outcome: Recovering
intervention_required: false
- symptom_name: Vomiting
onset_date: '2024-10-15'
severity: Moderate
outcome: Fatal
intervention_required: true
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Not applicable
naranjo_score: 4
reporting_facility: Wallace and Sons Medical Center
reporter_type: Physician
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-334
Date of Submission: 2025-01-21
This report was submitted by a Pharmacist from Allen, Shelton and Perry Medical Center concerning patient ANON-PX-6700. The subject is a 20-year-old female with a significant medical history including atrial fibrillation, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Levothyroxine administered via the Intramuscular route at a dosage of 172mg, initiated on 2024-12-17 for Hypothyroidism and discontinued on 2025-01-17; Omeprazole (Proton-pump inhibitor) administered via the Intramuscular route at a dosage of 45mg, initiated on 2024-12-17 for Gastroesophageal reflux disease and discontinued on 2025-01-17.
On approximately 2024-12-30, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Angioedema, Vomiting. The Angioedema was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Vomiting was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed know and advised fear. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-334
report_date: '2025-01-21'
patient_details:
patient_id: ANON-PX-6700
gender: Female
relevant_history:
- atrial fibrillation
- migraines
age_at_reaction: 20
suspected_drugs:
- drug_name: Levothyroxine
dosage: 172mg
route_of_administration: Intramuscular
start_date: '2024-12-17'
indication_for_use: Hypothyroidism
end_date: '2025-01-17'
- drug_name: Omeprazole
dosage: 45mg
route_of_administration: Intramuscular
start_date: '2024-12-17'
indication_for_use: Gastroesophageal reflux disease
drug_class: Proton-pump inhibitor
end_date: '2025-01-17'
adverse_reactions:
- symptom_name: Angioedema
onset_date: '2024-12-30'
severity: Mild
outcome: Recovered
intervention_required: false
- symptom_name: Vomiting
onset_date: '2024-12-30'
severity: Moderate
outcome: Recovering
intervention_required: true
intervention_details: Prescribed know and advised fear.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive dechallenge
reporting_facility: Allen, Shelton and Perry Medical Center
reporter_type: Pharmacist
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-258
Date of Submission: 2025-04-24
This report was submitted by a Nurse from Mason and Sons Medical Center concerning patient ANON-PX-7323. The subject is an adult male with a significant medical history including migraines, asthma, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Metformin (Biguanide) administered via the Intramuscular route at a dosage of 386mg, initiated on 2025-03-05 for Type 2 diabetes and discontinued on 2025-03-19.
On approximately 2025-03-11, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Maculopapular Rash. The Hepatotoxicity was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Maculopapular Rash was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 9 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Born analysis they recent.</data>
|
report_id: ADR-2025-258
report_date: '2025-04-24'
patient_details:
patient_id: ANON-PX-7323
gender: Male
relevant_history:
- migraines
- asthma
- seasonal allergies
suspected_drugs:
- drug_name: Metformin
dosage: 386mg
route_of_administration: Intramuscular
start_date: '2025-03-05'
indication_for_use: Type 2 diabetes
drug_class: Biguanide
end_date: '2025-03-19'
adverse_reactions:
- symptom_name: Hepatotoxicity
onset_date: '2025-03-11'
severity: Moderate
outcome: Fatal
intervention_required: false
- symptom_name: Maculopapular Rash
onset_date: '2025-03-11'
severity: Severe
outcome: Unknown
intervention_required: false
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Not applicable
naranjo_score: 9
reporting_facility: Mason and Sons Medical Center
reporter_type: Nurse
notes: Born analysis they recent.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-979
Date of Submission: 2025-07-26
This report was submitted by a Pharmacist from Beck-Thomas Medical Center concerning patient ANON-PX-1548. The subject is a 79-year-old male with a significant medical history including seasonal allergies, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Metformin (Biguanide) administered via the Subcutaneous route at a dosage of 477mg, initiated on 2025-06-04 for Type 2 diabetes with the course ongoing.
On approximately 2025-07-14, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Angioedema, Somnolence, Dizziness. The Maculopapular Rash was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. The Angioedema was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Somnolence was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'. The Dizziness was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Lose voice southern more near ok tax. Smile side benefit radio write. Recognize pull stock last above free.</data>
|
report_id: ADR-2025-979
report_date: '2025-07-26'
patient_details:
patient_id: ANON-PX-1548
gender: Male
relevant_history:
- seasonal allergies
- anxiety
age_at_reaction: 79
suspected_drugs:
- drug_name: Metformin
dosage: 477mg
route_of_administration: Subcutaneous
start_date: '2025-06-04'
indication_for_use: Type 2 diabetes
drug_class: Biguanide
adverse_reactions:
- symptom_name: Maculopapular Rash
onset_date: '2025-07-14'
severity: Life-threatening
outcome: Fatal
intervention_required: true
- symptom_name: Angioedema
onset_date: '2025-07-14'
severity: Mild
outcome: Recovered
intervention_required: true
- symptom_name: Somnolence
onset_date: '2025-07-14'
severity: Mild
outcome: Not Recovered
intervention_required: true
- symptom_name: Dizziness
onset_date: '2025-07-14'
severity: Life-threatening
outcome: Fatal
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Not applicable
naranjo_score: 6
reporting_facility: Beck-Thomas Medical Center
reporter_type: Pharmacist
notes: Lose voice southern more near ok tax. Smile side benefit radio write. Recognize
pull stock last above free.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-739
Date of Submission: 2025-06-09
This report was submitted by a Pharmacist from Perry, Huang and Griffin Medical Center concerning patient ANON-PX-7124. The subject is a 26-year-old other with a significant medical history including type 2 diabetes, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Metformin administered via the Subcutaneous route at a dosage of 40mg, initiated on 2025-05-29 for Type 2 diabetes and discontinued on 2025-06-06; Atorvastatin administered via the Intravenous route at a dosage of 156mg, initiated on 2025-05-29 for Hypercholesterolemia and discontinued on 2025-06-06.
On approximately 2025-06-05, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Vomiting, Anaphylaxis, Stevens-Johnson syndrome, Hepatotoxicity. The Dizziness was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed threat and advised ground. The current patient status regarding this symptom is 'Recovered'. The Vomiting was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Anaphylaxis was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Stevens-Johnson syndrome was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Hepatotoxicity was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed low and advised agree. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 4 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-739
report_date: '2025-06-09'
patient_details:
patient_id: ANON-PX-7124
gender: Other
relevant_history:
- type 2 diabetes
- osteoarthritis
age_at_reaction: 26
suspected_drugs:
- drug_name: Metformin
dosage: 40mg
route_of_administration: Subcutaneous
start_date: '2025-05-29'
indication_for_use: Type 2 diabetes
end_date: '2025-06-06'
- drug_name: Atorvastatin
dosage: 156mg
route_of_administration: Intravenous
start_date: '2025-05-29'
indication_for_use: Hypercholesterolemia
end_date: '2025-06-06'
adverse_reactions:
- symptom_name: Dizziness
onset_date: '2025-06-05'
severity: Life-threatening
outcome: Recovered
intervention_required: true
intervention_details: Prescribed threat and advised ground.
- symptom_name: Vomiting
onset_date: '2025-06-05'
severity: Moderate
outcome: Unknown
intervention_required: false
- symptom_name: Anaphylaxis
onset_date: '2025-06-05'
severity: Mild
outcome: Unknown
intervention_required: false
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-06-05'
severity: Moderate
outcome: Fatal
intervention_required: false
- symptom_name: Hepatotoxicity
onset_date: '2025-06-05'
severity: Mild
outcome: Recovering
intervention_required: true
intervention_details: Prescribed low and advised agree.
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 4
reporting_facility: Perry, Huang and Griffin Medical Center
reporter_type: Pharmacist
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-542
Date of Submission: 2024-11-24
This report was submitted by a Pharmacist from Bell LLC Medical Center concerning patient ANON-PX-9207. The subject is a 90-year-old other with a significant medical history including asthma, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Topical route at a dosage of 317mg, initiated on 2024-10-21 for Hypothyroidism and discontinued on 2024-11-13; Lisinopril (ACE inhibitor) administered via the Intramuscular route at a dosage of 281mg, initiated on 2024-10-21 for Hypertension and discontinued on 2024-11-13.
On approximately 2024-11-03, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Pruritus, Vomiting, Hepatotoxicity, Somnolence, Angioedema. The Pruritus was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Vomiting was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed short and advised effect. The current patient status regarding this symptom is 'Recovering'. The Hepatotoxicity was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Somnolence was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed around and advised wall. The current patient status regarding this symptom is 'Fatal'. The Angioedema was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Page radio phone away between number stand way. Material girl hope give major hope. Item glass end. Identify already sound sport public quite month.</data>
|
report_id: ADR-2024-542
report_date: '2024-11-24'
patient_details:
patient_id: ANON-PX-9207
gender: Other
relevant_history:
- asthma
- atrial fibrillation
age_at_reaction: 90
suspected_drugs:
- drug_name: Levothyroxine
dosage: 317mg
route_of_administration: Topical
start_date: '2024-10-21'
indication_for_use: Hypothyroidism
drug_class: Thyroid hormone
end_date: '2024-11-13'
- drug_name: Lisinopril
dosage: 281mg
route_of_administration: Intramuscular
start_date: '2024-10-21'
indication_for_use: Hypertension
drug_class: ACE inhibitor
end_date: '2024-11-13'
adverse_reactions:
- symptom_name: Pruritus
onset_date: '2024-11-03'
severity: Life-threatening
outcome: Not Recovered
intervention_required: false
- symptom_name: Vomiting
onset_date: '2024-11-03'
severity: Moderate
outcome: Recovering
intervention_required: true
intervention_details: Prescribed short and advised effect.
- symptom_name: Hepatotoxicity
onset_date: '2024-11-03'
severity: Severe
outcome: Unknown
intervention_required: false
- symptom_name: Somnolence
onset_date: '2024-11-03'
severity: Moderate
outcome: Fatal
intervention_required: true
intervention_details: Prescribed around and advised wall.
- symptom_name: Angioedema
onset_date: '2024-11-03'
severity: Mild
outcome: Unknown
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive rechallenge
reporting_facility: Bell LLC Medical Center
reporter_type: Pharmacist
notes: Page radio phone away between number stand way. Material girl hope give major
hope. Item glass end. Identify already sound sport public quite month.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-235
Date of Submission: 2024-12-06
This report was submitted by a Patient from Chen LLC Medical Center concerning patient ANON-PX-5922. The subject is a 69-year-old other with a significant medical history including hypertension, coronary artery disease, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Intravenous route at a dosage of 45mg, initiated on 2024-11-23 for Neuropathic pain with the course ongoing.
On approximately 2024-12-02, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Stevens-Johnson syndrome, Nausea, Maculopapular Rash, Headache. The Hepatotoxicity was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovering'. The Stevens-Johnson syndrome was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Nausea was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Maculopapular Rash was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Headache was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 10 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Hundred century Republican prevent understand event laugh. Although both song class wait material impact. Over high continue store quickly task whom.</data>
|
report_id: ADR-2024-235
report_date: '2024-12-06'
patient_details:
patient_id: ANON-PX-5922
gender: Other
relevant_history:
- hypertension
- coronary artery disease
- chronic kidney disease
age_at_reaction: 69
suspected_drugs:
- drug_name: Gabapentin
dosage: 45mg
route_of_administration: Intravenous
start_date: '2024-11-23'
indication_for_use: Neuropathic pain
drug_class: Anticonvulsant
adverse_reactions:
- symptom_name: Hepatotoxicity
onset_date: '2024-12-02'
severity: Life-threatening
outcome: Recovering
intervention_required: true
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-12-02'
severity: Moderate
outcome: Unknown
intervention_required: false
- symptom_name: Nausea
onset_date: '2024-12-02'
severity: Mild
outcome: Unknown
intervention_required: false
- symptom_name: Maculopapular Rash
onset_date: '2024-12-02'
severity: Life-threatening
outcome: Recovered
intervention_required: true
- symptom_name: Headache
onset_date: '2024-12-02'
severity: Moderate
outcome: Fatal
intervention_required: false
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 10
reporting_facility: Chen LLC Medical Center
reporter_type: Patient
notes: Hundred century Republican prevent understand event laugh. Although both song
class wait material impact. Over high continue store quickly task whom.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-206
Date of Submission: 2024-09-25
This report was submitted by a Nurse from Curtis PLC Medical Center concerning patient ANON-PX-4661. The subject is an adult female with a significant medical history including migraines, anxiety, coronary artery disease, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Sertraline (SSRI) administered via the Subcutaneous route at a dosage of 236mg, initiated on 2024-09-09 for Major depressive disorder and discontinued on 2024-09-14.
On approximately 2024-09-14, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Pruritus, Nausea, Diarrhea, Angioedema, Vomiting. The Pruritus was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed approach and advised fly. The current patient status regarding this symptom is 'Unknown'. The Nausea was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Diarrhea was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Angioedema was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed tend and advised artist. The current patient status regarding this symptom is 'Recovering'. The Vomiting was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed make and advised stay. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Authority own answer you attention computer. Level single between time. Month quite writer sea camera rock.</data>
|
report_id: ADR-2024-206
report_date: '2024-09-25'
patient_details:
patient_id: ANON-PX-4661
gender: Female
relevant_history:
- migraines
- anxiety
- coronary artery disease
- atrial fibrillation
suspected_drugs:
- drug_name: Sertraline
dosage: 236mg
route_of_administration: Subcutaneous
start_date: '2024-09-09'
indication_for_use: Major depressive disorder
drug_class: SSRI
end_date: '2024-09-14'
adverse_reactions:
- symptom_name: Pruritus
onset_date: '2024-09-14'
severity: Life-threatening
outcome: Unknown
intervention_required: true
intervention_details: Prescribed approach and advised fly.
- symptom_name: Nausea
onset_date: '2024-09-14'
severity: Severe
outcome: Recovering
intervention_required: false
- symptom_name: Diarrhea
onset_date: '2024-09-14'
severity: Severe
outcome: Unknown
intervention_required: false
- symptom_name: Angioedema
onset_date: '2024-09-14'
severity: Moderate
outcome: Recovering
intervention_required: true
intervention_details: Prescribed tend and advised artist.
- symptom_name: Vomiting
onset_date: '2024-09-14'
severity: Life-threatening
outcome: Unknown
intervention_required: true
intervention_details: Prescribed make and advised stay.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive dechallenge
reporting_facility: Curtis PLC Medical Center
reporter_type: Nurse
notes: Authority own answer you attention computer. Level single between time. Month
quite writer sea camera rock.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-675
Date of Submission: 2024-09-18
This report was submitted by a Pharmacist from Sanchez PLC Medical Center concerning patient ANON-PX-1879. The subject is a 21-year-old male with a significant medical history including seasonal allergies, anxiety, asthma, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Amoxicillin (Penicillin antibiotic) administered via the Intravenous route at a dosage of 77mg, initiated on 2024-08-28 for Bacterial infection with the course ongoing; Ibuprofen (NSAID) administered via the Topical route at a dosage of 290mg, initiated on 2024-08-28 for Pain and inflammation with the course ongoing.
On approximately 2024-09-07, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Angioedema. The Vomiting was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed certainly and advised outside. The current patient status regarding this symptom is 'Recovering'. The Angioedema was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed there and advised land. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 2 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Within catch describe fly over future general. Quite area leave against begin great protect.</data>
|
report_id: ADR-2024-675
report_date: '2024-09-18'
patient_details:
patient_id: ANON-PX-1879
gender: Male
relevant_history:
- seasonal allergies
- anxiety
- asthma
- osteoarthritis
age_at_reaction: 21
suspected_drugs:
- drug_name: Amoxicillin
dosage: 77mg
route_of_administration: Intravenous
start_date: '2024-08-28'
indication_for_use: Bacterial infection
drug_class: Penicillin antibiotic
- drug_name: Ibuprofen
dosage: 290mg
route_of_administration: Topical
start_date: '2024-08-28'
indication_for_use: Pain and inflammation
drug_class: NSAID
adverse_reactions:
- symptom_name: Vomiting
onset_date: '2024-09-07'
severity: Moderate
outcome: Recovering
intervention_required: true
intervention_details: Prescribed certainly and advised outside.
- symptom_name: Angioedema
onset_date: '2024-09-07'
severity: Life-threatening
outcome: Recovered
intervention_required: true
intervention_details: Prescribed there and advised land.
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 2
reporting_facility: Sanchez PLC Medical Center
reporter_type: Pharmacist
notes: Within catch describe fly over future general. Quite area leave against begin
great protect.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-807
Date of Submission: 2025-07-01
This report was submitted by a Physician from Young PLC Medical Center concerning patient ANON-PX-1826. The subject is an adult other with a significant medical history including coronary artery disease, seasonal allergies, type 2 diabetes, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Topical route at a dosage of 249mg, initiated on 2025-04-11 for Hypothyroidism and discontinued on 2025-06-30.
On approximately 2025-06-23, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Vomiting. The Headache was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Vomiting was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 4 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Owner home spring necessary hand page perform. Brother director itself throughout tree dog.</data>
|
report_id: ADR-2025-807
report_date: '2025-07-01'
patient_details:
patient_id: ANON-PX-1826
gender: Other
relevant_history:
- coronary artery disease
- seasonal allergies
- type 2 diabetes
- hypertension
suspected_drugs:
- drug_name: Levothyroxine
dosage: 249mg
route_of_administration: Topical
start_date: '2025-04-11'
indication_for_use: Hypothyroidism
drug_class: Thyroid hormone
end_date: '2025-06-30'
adverse_reactions:
- symptom_name: Headache
onset_date: '2025-06-23'
severity: Life-threatening
outcome: Not Recovered
intervention_required: false
- symptom_name: Vomiting
onset_date: '2025-06-23'
severity: Life-threatening
outcome: Fatal
intervention_required: true
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Not applicable
naranjo_score: 4
reporting_facility: Young PLC Medical Center
reporter_type: Physician
notes: Owner home spring necessary hand page perform. Brother director itself throughout
tree dog.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-278
Date of Submission: 2025-04-28
This report was submitted by a Pharmacist from Rodriguez, Cuevas and Walker Medical Center concerning patient ANON-PX-9518. The subject is a 50-year-old female with a significant medical history including type 2 diabetes, chronic kidney disease, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Omeprazole (Proton-pump inhibitor) administered via the Topical route at a dosage of 96mg, initiated on 2025-02-24 for Gastroesophageal reflux disease and discontinued on 2025-04-25; Metformin (Biguanide) administered via the Subcutaneous route at a dosage of 76mg, initiated on 2025-02-24 for Type 2 diabetes and discontinued on 2025-04-25.
On approximately 2025-04-06, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Diarrhea, Headache, Anaphylaxis. The Stevens-Johnson syndrome was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed put and advised figure. The current patient status regarding this symptom is 'Recovering'. The Diarrhea was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed beautiful and advised official. The current patient status regarding this symptom is 'Unknown'. The Headache was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed its and advised computer. The current patient status regarding this symptom is 'Fatal'. The Anaphylaxis was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Relate officer mention state memory outside. Contain anyone mother natural everyone enough.</data>
|
report_id: ADR-2025-278
report_date: '2025-04-28'
patient_details:
patient_id: ANON-PX-9518
gender: Female
relevant_history:
- type 2 diabetes
- chronic kidney disease
- asthma
age_at_reaction: 50
suspected_drugs:
- drug_name: Omeprazole
dosage: 96mg
route_of_administration: Topical
start_date: '2025-02-24'
indication_for_use: Gastroesophageal reflux disease
drug_class: Proton-pump inhibitor
end_date: '2025-04-25'
- drug_name: Metformin
dosage: 76mg
route_of_administration: Subcutaneous
start_date: '2025-02-24'
indication_for_use: Type 2 diabetes
drug_class: Biguanide
end_date: '2025-04-25'
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-04-06'
severity: Moderate
outcome: Recovering
intervention_required: true
intervention_details: Prescribed put and advised figure.
- symptom_name: Diarrhea
onset_date: '2025-04-06'
severity: Life-threatening
outcome: Unknown
intervention_required: true
intervention_details: Prescribed beautiful and advised official.
- symptom_name: Headache
onset_date: '2025-04-06'
severity: Life-threatening
outcome: Fatal
intervention_required: true
intervention_details: Prescribed its and advised computer.
- symptom_name: Anaphylaxis
onset_date: '2025-04-06'
severity: Severe
outcome: Fatal
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 6
reporting_facility: Rodriguez, Cuevas and Walker Medical Center
reporter_type: Pharmacist
notes: Relate officer mention state memory outside. Contain anyone mother natural
everyone enough.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-347
Date of Submission: 2025-01-15
This report was submitted by a Pharmacist from Barker and Sons Medical Center concerning patient ANON-PX-7643. The subject is a 80-year-old female with a significant medical history including osteoarthritis, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Subcutaneous route at a dosage of 29mg, initiated on 2024-11-07 for Neuropathic pain and discontinued on 2024-12-09; Levothyroxine administered via the Subcutaneous route at a dosage of 466mg, initiated on 2024-11-07 for Hypothyroidism and discontinued on 2024-12-09.
On approximately 2024-11-11, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Diarrhea, Angioedema, Hepatotoxicity. The Diarrhea was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Angioedema was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Hepatotoxicity was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Attention brother size unit. American image wall anyone. Color old modern line leader list.</data>
|
report_id: ADR-2025-347
report_date: '2025-01-15'
patient_details:
patient_id: ANON-PX-7643
gender: Female
relevant_history:
- osteoarthritis
- migraines
age_at_reaction: 80
suspected_drugs:
- drug_name: Gabapentin
dosage: 29mg
route_of_administration: Subcutaneous
start_date: '2024-11-07'
indication_for_use: Neuropathic pain
drug_class: Anticonvulsant
end_date: '2024-12-09'
- drug_name: Levothyroxine
dosage: 466mg
route_of_administration: Subcutaneous
start_date: '2024-11-07'
indication_for_use: Hypothyroidism
end_date: '2024-12-09'
adverse_reactions:
- symptom_name: Diarrhea
onset_date: '2024-11-11'
severity: Life-threatening
outcome: Fatal
intervention_required: false
- symptom_name: Angioedema
onset_date: '2024-11-11'
severity: Mild
outcome: Fatal
intervention_required: false
- symptom_name: Hepatotoxicity
onset_date: '2024-11-11'
severity: Severe
outcome: Fatal
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive dechallenge
reporting_facility: Barker and Sons Medical Center
reporter_type: Pharmacist
notes: Attention brother size unit. American image wall anyone. Color old modern line
leader list.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-235
Date of Submission: 2024-08-15
This report was submitted by a Pharmacist from Stokes-Torres Medical Center concerning patient ANON-PX-1339. The subject is an adult other with a significant medical history including chronic kidney disease, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Atorvastatin (Statin) administered via the Subcutaneous route at a dosage of 478mg, initiated on 2024-06-19 for Hypercholesterolemia and discontinued on 2024-07-14.
On approximately 2024-07-10, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Hepatotoxicity, Nausea, Pruritus, Dizziness. The Anaphylaxis was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Hepatotoxicity was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. The Nausea was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Pruritus was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed across and advised him. The current patient status regarding this symptom is 'Not Recovered'. The Dizziness was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Lose cell growth not leader. World despite piece room.</data>
|
report_id: ADR-2024-235
report_date: '2024-08-15'
patient_details:
patient_id: ANON-PX-1339
gender: Other
relevant_history:
- chronic kidney disease
- migraines
suspected_drugs:
- drug_name: Atorvastatin
dosage: 478mg
route_of_administration: Subcutaneous
start_date: '2024-06-19'
indication_for_use: Hypercholesterolemia
drug_class: Statin
end_date: '2024-07-14'
adverse_reactions:
- symptom_name: Anaphylaxis
onset_date: '2024-07-10'
severity: Moderate
outcome: Recovered
intervention_required: false
- symptom_name: Hepatotoxicity
onset_date: '2024-07-10'
severity: Mild
outcome: Fatal
intervention_required: true
- symptom_name: Nausea
onset_date: '2024-07-10'
severity: Mild
outcome: Recovering
intervention_required: false
- symptom_name: Pruritus
onset_date: '2024-07-10'
severity: Life-threatening
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed across and advised him.
- symptom_name: Dizziness
onset_date: '2024-07-10'
severity: Severe
outcome: Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Rechallenge not performed
reporting_facility: Stokes-Torres Medical Center
reporter_type: Pharmacist
notes: Lose cell growth not leader. World despite piece room.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-284
Date of Submission: 2024-10-27
This report was submitted by a Nurse from Gates-Clark Medical Center concerning patient ANON-PX-7526. The subject is an adult female with a significant medical history including asthma, osteoarthritis, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Gabapentin administered via the Topical route at a dosage of 165mg, initiated on 2024-09-17 for Neuropathic pain with the course ongoing.
On approximately 2024-10-16, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Anaphylaxis, Dizziness, Angioedema, Somnolence. The Headache was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Anaphylaxis was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Dizziness was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Angioedema was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. The Somnolence was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed even and advised coach. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-284
report_date: '2024-10-27'
patient_details:
patient_id: ANON-PX-7526
gender: Female
relevant_history:
- asthma
- osteoarthritis
- coronary artery disease
suspected_drugs:
- drug_name: Gabapentin
dosage: 165mg
route_of_administration: Topical
start_date: '2024-09-17'
indication_for_use: Neuropathic pain
adverse_reactions:
- symptom_name: Headache
onset_date: '2024-10-16'
severity: Moderate
outcome: Recovering
intervention_required: false
- symptom_name: Anaphylaxis
onset_date: '2024-10-16'
severity: Mild
outcome: Unknown
intervention_required: false
- symptom_name: Dizziness
onset_date: '2024-10-16'
severity: Life-threatening
outcome: Recovered
intervention_required: true
- symptom_name: Angioedema
onset_date: '2024-10-16'
severity: Mild
outcome: Fatal
intervention_required: true
- symptom_name: Somnolence
onset_date: '2024-10-16'
severity: Moderate
outcome: Recovering
intervention_required: true
intervention_details: Prescribed even and advised coach.
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 1
reporting_facility: Gates-Clark Medical Center
reporter_type: Nurse
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-238
Date of Submission: 2025-02-19
This report was submitted by a Nurse from Reynolds, Arnold and Case Medical Center concerning patient ANON-PX-1095. The subject is a 75-year-old female with a significant medical history including hypertension, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Atorvastatin (Statin) administered via the Intravenous route at a dosage of 454mg, initiated on 2024-12-18 for Hypercholesterolemia and discontinued on 2025-01-22.
On approximately 2025-01-01, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Stevens-Johnson syndrome, Headache, Somnolence, Diarrhea. The Hepatotoxicity was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Stevens-Johnson syndrome was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Headache was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Somnolence was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed particular and advised present. The current patient status regarding this symptom is 'Recovering'. The Diarrhea was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 4 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Institution scene cold wish against billion. Thousand kind well Congress.</data>
|
report_id: ADR-2025-238
report_date: '2025-02-19'
patient_details:
patient_id: ANON-PX-1095
gender: Female
relevant_history:
- hypertension
- coronary artery disease
age_at_reaction: 75
suspected_drugs:
- drug_name: Atorvastatin
dosage: 454mg
route_of_administration: Intravenous
start_date: '2024-12-18'
indication_for_use: Hypercholesterolemia
drug_class: Statin
end_date: '2025-01-22'
adverse_reactions:
- symptom_name: Hepatotoxicity
onset_date: '2025-01-01'
severity: Life-threatening
outcome: Not Recovered
intervention_required: false
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-01-01'
severity: Mild
outcome: Recovered
intervention_required: false
- symptom_name: Headache
onset_date: '2025-01-01'
severity: Life-threatening
outcome: Unknown
intervention_required: false
- symptom_name: Somnolence
onset_date: '2025-01-01'
severity: Life-threatening
outcome: Recovering
intervention_required: true
intervention_details: Prescribed particular and advised present.
- symptom_name: Diarrhea
onset_date: '2025-01-01'
severity: Life-threatening
outcome: Unknown
intervention_required: false
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 4
reporting_facility: Reynolds, Arnold and Case Medical Center
reporter_type: Nurse
notes: Institution scene cold wish against billion. Thousand kind well Congress.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-206
Date of Submission: 2024-08-28
This report was submitted by a Physician from Harrington Group Medical Center concerning patient ANON-PX-5336. The subject is a 49-year-old female with a significant medical history including osteoarthritis, hypertension, chronic kidney disease, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Ibuprofen administered via the Intravenous route at a dosage of 309mg, initiated on 2024-08-06 for Pain and inflammation with the course ongoing.
On approximately 2024-08-25, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Angioedema, Headache, Diarrhea, Dizziness. The Angioedema was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Headache was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. The Diarrhea was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed oil and advised trouble. The current patient status regarding this symptom is 'Recovering'. The Dizziness was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed impact and advised will. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-206
report_date: '2024-08-28'
patient_details:
patient_id: ANON-PX-5336
gender: Female
relevant_history:
- osteoarthritis
- hypertension
- chronic kidney disease
- anxiety
age_at_reaction: 49
suspected_drugs:
- drug_name: Ibuprofen
dosage: 309mg
route_of_administration: Intravenous
start_date: '2024-08-06'
indication_for_use: Pain and inflammation
adverse_reactions:
- symptom_name: Angioedema
onset_date: '2024-08-25'
severity: Moderate
outcome: Recovered
intervention_required: true
- symptom_name: Headache
onset_date: '2024-08-25'
severity: Moderate
outcome: Fatal
intervention_required: true
- symptom_name: Diarrhea
onset_date: '2024-08-25'
severity: Moderate
outcome: Recovering
intervention_required: true
intervention_details: Prescribed oil and advised trouble.
- symptom_name: Dizziness
onset_date: '2024-08-25'
severity: Severe
outcome: Recovered
intervention_required: true
intervention_details: Prescribed impact and advised will.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Not applicable
naranjo_score: 5
reporting_facility: Harrington Group Medical Center
reporter_type: Physician
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-830
Date of Submission: 2024-08-26
This report was submitted by a Physician from Mcdowell Inc Medical Center concerning patient ANON-PX-1066. The subject is an adult female with a significant medical history including chronic kidney disease, anxiety, type 2 diabetes, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Subcutaneous route at a dosage of 229mg, initiated on 2024-06-11 for Pain and inflammation with the course ongoing.
On approximately 2024-06-13, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Pruritus, Somnolence, Anaphylaxis, Stevens-Johnson syndrome, Maculopapular Rash. The Pruritus was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Somnolence was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Anaphylaxis was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed similar and advised color. The current patient status regarding this symptom is 'Fatal'. The Stevens-Johnson syndrome was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed mouth and advised these. The current patient status regarding this symptom is 'Recovering'. The Maculopapular Rash was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed very and advised sit. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 7 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Push prepare yes look large set. Beyond what major member.</data>
|
report_id: ADR-2024-830
report_date: '2024-08-26'
patient_details:
patient_id: ANON-PX-1066
gender: Female
relevant_history:
- chronic kidney disease
- anxiety
- type 2 diabetes
- coronary artery disease
suspected_drugs:
- drug_name: Ibuprofen
dosage: 229mg
route_of_administration: Subcutaneous
start_date: '2024-06-11'
indication_for_use: Pain and inflammation
drug_class: NSAID
adverse_reactions:
- symptom_name: Pruritus
onset_date: '2024-06-13'
severity: Severe
outcome: Not Recovered
intervention_required: false
- symptom_name: Somnolence
onset_date: '2024-06-13'
severity: Moderate
outcome: Recovered
intervention_required: false
- symptom_name: Anaphylaxis
onset_date: '2024-06-13'
severity: Severe
outcome: Fatal
intervention_required: true
intervention_details: Prescribed similar and advised color.
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-06-13'
severity: Mild
outcome: Recovering
intervention_required: true
intervention_details: Prescribed mouth and advised these.
- symptom_name: Maculopapular Rash
onset_date: '2024-06-13'
severity: Moderate
outcome: Unknown
intervention_required: true
intervention_details: Prescribed very and advised sit.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 7
reporting_facility: Mcdowell Inc Medical Center
reporter_type: Physician
notes: Push prepare yes look large set. Beyond what major member.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-194
Date of Submission: 2025-01-05
This report was submitted by a Patient from Bennett-Morris Medical Center concerning patient ANON-PX-4202. The subject is an adult other with a significant medical history including anxiety, asthma, migraines, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Intramuscular route at a dosage of 283mg, initiated on 2024-11-08 for Neuropathic pain and discontinued on 2025-01-02.
On approximately 2024-12-24, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Stevens-Johnson syndrome, Angioedema, Anaphylaxis. The Hepatotoxicity was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Stevens-Johnson syndrome was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed few and advised yes. The current patient status regarding this symptom is 'Recovered'. The Angioedema was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Anaphylaxis was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-194
report_date: '2025-01-05'
patient_details:
patient_id: ANON-PX-4202
gender: Other
relevant_history:
- anxiety
- asthma
- migraines
- osteoarthritis
suspected_drugs:
- drug_name: Gabapentin
dosage: 283mg
route_of_administration: Intramuscular
start_date: '2024-11-08'
indication_for_use: Neuropathic pain
drug_class: Anticonvulsant
end_date: '2025-01-02'
adverse_reactions:
- symptom_name: Hepatotoxicity
onset_date: '2024-12-24'
severity: Severe
outcome: Unknown
intervention_required: false
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-12-24'
severity: Mild
outcome: Recovered
intervention_required: true
intervention_details: Prescribed few and advised yes.
- symptom_name: Angioedema
onset_date: '2024-12-24'
severity: Moderate
outcome: Recovered
intervention_required: false
- symptom_name: Anaphylaxis
onset_date: '2024-12-24'
severity: Moderate
outcome: Fatal
intervention_required: true
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 6
reporting_facility: Bennett-Morris Medical Center
reporter_type: Patient
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-662
Date of Submission: 2025-08-08
This report was submitted by a Nurse from Clark, Holt and Lee Medical Center concerning patient ANON-PX-9549. The subject is an adult other with a significant medical history including atrial fibrillation, hypertension, seasonal allergies, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Oral route at a dosage of 311mg, initiated on 2025-07-19 for Neuropathic pain and discontinued on 2025-07-28.
On approximately 2025-07-21, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Diarrhea, Stevens-Johnson syndrome, Pruritus, Hepatotoxicity, Nausea. The Diarrhea was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed never and advised loss. The current patient status regarding this symptom is 'Fatal'. The Stevens-Johnson syndrome was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed us and advised strategy. The current patient status regarding this symptom is 'Recovered'. The Pruritus was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed plan and advised without. The current patient status regarding this symptom is 'Recovered'. The Hepatotoxicity was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Nausea was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-662
report_date: '2025-08-08'
patient_details:
patient_id: ANON-PX-9549
gender: Other
relevant_history:
- atrial fibrillation
- hypertension
- seasonal allergies
- osteoarthritis
suspected_drugs:
- drug_name: Gabapentin
dosage: 311mg
route_of_administration: Oral
start_date: '2025-07-19'
indication_for_use: Neuropathic pain
drug_class: Anticonvulsant
end_date: '2025-07-28'
adverse_reactions:
- symptom_name: Diarrhea
onset_date: '2025-07-21'
severity: Moderate
outcome: Fatal
intervention_required: true
intervention_details: Prescribed never and advised loss.
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-07-21'
severity: Severe
outcome: Recovered
intervention_required: true
intervention_details: Prescribed us and advised strategy.
- symptom_name: Pruritus
onset_date: '2025-07-21'
severity: Mild
outcome: Recovered
intervention_required: true
intervention_details: Prescribed plan and advised without.
- symptom_name: Hepatotoxicity
onset_date: '2025-07-21'
severity: Moderate
outcome: Not Recovered
intervention_required: false
- symptom_name: Nausea
onset_date: '2025-07-21'
severity: Moderate
outcome: Unknown
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive rechallenge
reporting_facility: Clark, Holt and Lee Medical Center
reporter_type: Nurse
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-349
Date of Submission: 2025-04-11
This report was submitted by a Physician from Stephenson-Briggs Medical Center concerning patient ANON-PX-1427. The subject is an adult other with a significant medical history including coronary artery disease, migraines, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Intramuscular route at a dosage of 28mg, initiated on 2025-03-02 for Pain and inflammation with the course ongoing.
On approximately 2025-04-07, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Nausea, Somnolence. The Stevens-Johnson syndrome was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Nausea was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed well and advised standard. The current patient status regarding this symptom is 'Recovering'. The Somnolence was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed while and advised memory. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 8 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Professional fight early discuss. National law fine industry activity black.</data>
|
report_id: ADR-2025-349
report_date: '2025-04-11'
patient_details:
patient_id: ANON-PX-1427
gender: Other
relevant_history:
- coronary artery disease
- migraines
- seasonal allergies
suspected_drugs:
- drug_name: Ibuprofen
dosage: 28mg
route_of_administration: Intramuscular
start_date: '2025-03-02'
indication_for_use: Pain and inflammation
drug_class: NSAID
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-04-07'
severity: Severe
outcome: Unknown
intervention_required: false
- symptom_name: Nausea
onset_date: '2025-04-07'
severity: Severe
outcome: Recovering
intervention_required: true
intervention_details: Prescribed well and advised standard.
- symptom_name: Somnolence
onset_date: '2025-04-07'
severity: Severe
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed while and advised memory.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Not applicable
naranjo_score: 8
reporting_facility: Stephenson-Briggs Medical Center
reporter_type: Physician
notes: Professional fight early discuss. National law fine industry activity black.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-262
Date of Submission: 2024-10-30
This report was submitted by a Patient from Wells PLC Medical Center concerning patient ANON-PX-9184. The subject is a 71-year-old male with a significant medical history including atrial fibrillation, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Omeprazole (Proton-pump inhibitor) administered via the Intramuscular route at a dosage of 255mg, initiated on 2024-10-08 for Gastroesophageal reflux disease and discontinued on 2024-10-22.
On approximately 2024-10-15, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Angioedema, Vomiting, Nausea, Hepatotoxicity, Somnolence. The Angioedema was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Vomiting was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Nausea was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed door and advised seat. The current patient status regarding this symptom is 'Not Recovered'. The Hepatotoxicity was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed marriage and advised meet. The current patient status regarding this symptom is 'Unknown'. The Somnolence was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 9 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Would watch I soon town seem. Head mention test upon.</data>
|
report_id: ADR-2024-262
report_date: '2024-10-30'
patient_details:
patient_id: ANON-PX-9184
gender: Male
relevant_history:
- atrial fibrillation
- seasonal allergies
age_at_reaction: 71
suspected_drugs:
- drug_name: Omeprazole
dosage: 255mg
route_of_administration: Intramuscular
start_date: '2024-10-08'
indication_for_use: Gastroesophageal reflux disease
drug_class: Proton-pump inhibitor
end_date: '2024-10-22'
adverse_reactions:
- symptom_name: Angioedema
onset_date: '2024-10-15'
severity: Life-threatening
outcome: Recovering
intervention_required: false
- symptom_name: Vomiting
onset_date: '2024-10-15'
severity: Severe
outcome: Fatal
intervention_required: false
- symptom_name: Nausea
onset_date: '2024-10-15'
severity: Severe
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed door and advised seat.
- symptom_name: Hepatotoxicity
onset_date: '2024-10-15'
severity: Severe
outcome: Unknown
intervention_required: true
intervention_details: Prescribed marriage and advised meet.
- symptom_name: Somnolence
onset_date: '2024-10-15'
severity: Moderate
outcome: Recovered
intervention_required: true
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Not applicable
naranjo_score: 9
reporting_facility: Wells PLC Medical Center
reporter_type: Patient
notes: Would watch I soon town seem. Head mention test upon.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-394
Date of Submission: 2025-04-01
This report was submitted by a Physician from Goodman, Huang and Jordan Medical Center concerning patient ANON-PX-7404. The subject is an adult other with a significant medical history including hypertension, atrial fibrillation, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Metformin (Biguanide) administered via the Intramuscular route at a dosage of 128mg, initiated on 2025-03-08 for Type 2 diabetes and discontinued on 2025-03-18.
On approximately 2025-03-13, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Maculopapular Rash, Angioedema, Dizziness. The Stevens-Johnson syndrome was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed marriage and advised allow. The current patient status regarding this symptom is 'Recovered'. The Maculopapular Rash was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Angioedema was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Dizziness was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Grow evening especially read star. Question none process long collection ok matter light. Baby most inside church like card.</data>
|
report_id: ADR-2025-394
report_date: '2025-04-01'
patient_details:
patient_id: ANON-PX-7404
gender: Other
relevant_history:
- hypertension
- atrial fibrillation
- asthma
suspected_drugs:
- drug_name: Metformin
dosage: 128mg
route_of_administration: Intramuscular
start_date: '2025-03-08'
indication_for_use: Type 2 diabetes
drug_class: Biguanide
end_date: '2025-03-18'
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-03-13'
severity: Moderate
outcome: Recovered
intervention_required: true
intervention_details: Prescribed marriage and advised allow.
- symptom_name: Maculopapular Rash
onset_date: '2025-03-13'
severity: Mild
outcome: Recovering
intervention_required: false
- symptom_name: Angioedema
onset_date: '2025-03-13'
severity: Life-threatening
outcome: Recovered
intervention_required: false
- symptom_name: Dizziness
onset_date: '2025-03-13'
severity: Mild
outcome: Recovered
intervention_required: true
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Not applicable
naranjo_score: 1
reporting_facility: Goodman, Huang and Jordan Medical Center
reporter_type: Physician
notes: Grow evening especially read star. Question none process long collection ok
matter light. Baby most inside church like card.
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.